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ABSTRACT 
Obesity is a global epidemic characterized by an expansion of adipose tissue. Adipose 
tissue, composed of adipocytes and a stromal vascular fraction, is an endocrine organ that regulates 
whole body homeostasis. Obesity leads to the dysregulation of adipocytes and is often associated 
with increased susceptibility to metabolic diseases such as Type II diabetes mellitus (T2DM). 
Understanding the mechanisms by which adipocyte function and development are regulated is 
crucial. Mitochondrial pyruvate carriers (MPCs) are transmembrane proteins that transport 
pyruvate from the cytosol into the mitochondrial matrix to generate acetyl CoA. Although MPCs 
have been studied extensively, their roles in adipocytes are not known. To study the role of MPCs 
in adipocytes, we assessed the requirement of MPC1 for adipogenesis, the expression of MPCs in 
adipose tissue, and the nutritional regulation of MPCs during diet-induced obesity (DIO). Our 
novel studies show that MPCs are not required for adipogenesis but are highly expressed in brown 
adipose tissue (BAT), and that MPC expression levels are regulated by DIO in the BAT of male 
mice.  KAT8 is a lysine acetyltransferase that plays a role in DNA damage repair, apoptosis, and 
tumorigenesis. Although KAT8 is an important component of many cellular processes, its role in 
adipocytes is unknown. Notably, a large genome-wide association study identified KAT8 as part 
of a novel locus that significantly contributed to variations in body mass index and other metabolic 
phenotypes. Hence, we examined the expression and regulation of KAT8 in adipocytes. In vitro 
experiments revealed that KAT8 expression was required for adipogenesis but did not affect 
turnover rates of peroxisome proliferator-activated receptor g (PPARg) and fatty acid synthase 
(FASN). Our novel in vivo data demonstrates that KAT8 is highly expressed at the protein level in 
white adipose tissue (WAT) depots, upregulated by DIO in the iWAT and gWAT of male mice, 
and upregulated by refeeding after fasting in adipose tissue (AT) depots. We have observed that 
 xii 
KAT8 expression is required for adipogenesis in vitro and is nutritionally regulated in WAT in 
vivo. Collectively, these studies have identified an epigenetic modifier that plays a previously 
unidentified role in adipocyte development and function.
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CHAPTER 1. GENERAL INTRODUCTION 
1.1 Adipocytes 
Obesity is a disease with increasing prevalence that is characterized by an excess 
accumulation of adipose tissue.  In the past two decades, obesity prevalence has increased from 
30.5% to 42.4% [1], fueling a parallel increase in associated metabolic diseases such as type 2 
diabetes (T2DM). According to the CDC, diabetes is the 7th leading cause of death, and over 34 
million people have diabetes in the United States [2]. Adipose tissue, once thought to be nothing 
more than a site for energy storage in the form of triacylglycerols (TAGs), is now recognized as a 
complex endocrine organ with essential roles in energy homeostasis and metabolism. Therefore, 
the coupled epidemics of obesity and metabolic dysfunction have driven intensive research to 
explore the roles and functions of adipocytes and adipose tissue [3–5]. 
Adipose tissue is composed of adipocytes and a stromal vascular fraction comprised of 
preadipocytes, fibroblasts, endothelial cells, macrophages, and leukocytes. Adipose tissue is  
distributed throughout the body and expands to accommodate excess lipid [6].  Expansion occurs 
by hypertrophy, hyperplasia, or a combination of both processes. In humans, there are two general 
types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). Yet, it 
should be noted that a new type of adipocyte called beige or brite adipocytes have been identified 
and extensively studied in the last decade. Beige adipocytes are found in WAT and have enriched 
expression of BAT markers [7,8]. 
Brown adipocytes in BAT are characterized by their multilocular morphology and high 
mitochondrial content, which contributes to its brown color. BAT’s highly specialized role is to 
generate heat through  non-shivering thermogenesis [5,6]. This process is mediated by uncoupling 
protein 1 (UCP1), which uncouples fatty acid oxidation from oxidative phosphorylation and ATP 
synthesis by dissipating the proton gradient across the mitochondrial membrane as heat. Brown 
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adipose tissue (BAT) is relatively abundant in neonatal stages and was once thought to be 
completely replaced by white adipose tissue (WAT) in humans with aging [6,9]. More recent 
studies, however, have revealed that BAT is present in adults. These studies reveal that BAT  is 
metabolically active in the cervical, axillary, and paraspinal areas, and that it may account for 1-
2% of the total fat in humans [10–13].  
WAT is responsible for the synthesis and storage of TAGs during periods of energy 
surplus, and for the hydrolysis of TAGs via lipolysis to generate free fatty acids (FFAs) and 
glycerol during periods of energy deficiency [3,14]. WAT makes up the majority of the adipose 
tissue volume in the human body and increases in volume with age. WAT is categorized in two 
ways: visceral WAT and subcutaneous WAT. Visceral WAT is located in the abdominal cavity 
and lines the internal organs. Visceral WAT represents approximately 6-20% of the total body fat, 
and is typically more abundant in males than females [15]. There are four types of visceral WAT 
in humans: mesenteric, omental, peritoneal, and perirenal [6]. Disruption of homeostasis in 
visceral WAT can lead to increased mortality and metabolic complications, such as insulin 
resistance, type 2 diabetes, and hyperlipidemia [6,16–18]. Accretion of adipose tissue 
predominantly localized to visceral depots is often referred to as apple-shaped fat distribution.   
On the other hand, subcutaneous adipose tissue is located just below the skin.  It comprises 
approximately 80-90% of the total body fat in lean, healthy individuals, and is more abundant in 
females [13,15]. In contrast to visceral WAT, subcutaneous WAT has been suggested to have a 
protective metabolic role  [19]. Increased distribution of subcutaneous WAT in the gluteofemoral 
regions, referred to as pear-shaped distribution, has been associated with a lower risk of developing 
type 2 diabetes and with improved insulin sensitivity. Transplantation of subcutaneous WAT into 
visceral epididymal WAT cavities of C57BL/6 mice resulted in reduced body weight, fat mass, 
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glucose levels, and insulin levels [20]. When the storage capacity of subcutaneous WAT is 
exceeded during states of positive energy balance, lipid is then displaced and ectopically deposited 
in areas outside of the adipose tissue, which can have detrimental metabolic effects [13].  
Adipocytes have several features that are critical to their effects on whole-body metabolic 
function. These include the storage and release of lipids, the secretion of adipokines, and the ability 
to respond to insulin. Mature white adipocytes are  unilocular cells containing a single large lipid 
droplet that occupies most of the cell, with the nucleus and other organelles pushed against the 
plasma membrane [21]. The primary function of adipocytes is to store lipid. Adipocytes regulate 
both lipid synthesis (lipogenesis) and lipid catabolism (lipolysis) in response to the body’s energy 
status [22]. When substrate availability is high, such as in the fed state, lipids accumulate, in the 
form of TAGs, in adipocytes via two processes: lipogenesis and fatty acid (FA) uptake [22]. 
Conversely, lipolysis is the process by which TAGs are broken down into free fatty acids (FFAs) 
and glycerol via a series of lipases [22] in conditions of low substrate availability. In addition to 
lipid metabolism, adipocytes exclusively synthesize and secrete three vital adipokines: leptin 
[23,24], adiponectin [25], and resistin [26]. Leptin, the first adipokine to be characterized, is 
referred to as the “satiety hormone” because it is secreted from adipocytes and signals to the 
hypothalamus to decrease food intake and  increase energy expenditure [27]. Adiponectin, 
identified in 1995 as adipocyte complement-related protein of 30 kDa (Acrp30) [25], positively 
regulates adipogenesis, maintains insulin sensitivity, and has anti-inflammatory effects [28]. 
Resistin, the most recently discovered  adipocyte hormone, induces insulin resistance [28]. 
Resistin, which is derived from adipocytes in mice and from macrophages in humans, mediates 
the same metabolic and inflammatory responses in both species  [28]. Disruptions in any adipocyte 
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functions result in metabolic dysfunctions commonly associated with obesity and metabolic 
syndrome.  Hence, it is important to have properly functioning adipocytes.  
Metabolic syndrome defines a cluster of cardiometabolic risk factors that increase 
susceptibility for metabolic diseases such as type 2 diabetes mellitus (T2DM), heart disease, and 
stroke [29,30]. These risk factors include hypertension, hyperglycemia, excess abdominal fat, and 
abnormal cholesterol and TG levels [30]. Having three or more of these risk factors greatly 
increases the occurrence of diseases such as T2DM. T2DM, characterized by insulin resistance 
and hyperglycemia [31],  is the most common form of diabetes and accounts for an estimated 95% 
of all diabetes diagnoses [2]. Factors associated with increased susceptibility of developing T2DM 
are obesity, genetic predisposition, aging, and physical inactivity [32]. It is well-known that excess 
adipose tissue is directly associated with insulin resistance, and that glucose homeostasis is 
dependent upon the functionality of adipose tissue. This information highlights the need to study 
adipose tissue dysfunction and the mechanisms by which fat contributes to obesity-related T2DM. 
The excessive expansion of adipose tissue observed in obesity is driven by an increase in 
the generation of new adipocytes (hyperplasia) or an increase in adipocyte size (hypertrophy), or 
by a combination of both [6]. Hyperplastic expansion of adipose tissue, predominant in 
subcutaneous WAT, is characterized by an increase in differentiation of adipocyte precursor cells 
into preadipocytes and then adipocytes [6]. Expansion due to hypertrophy often results in 
abnormalities associated with necrosis, such as macrophage infiltration [33], increased production 
and secretion of inflammatory cytokines, adipose tissue hypoxia, and elevated basal lipolysis rates 
[34–36]. However, hypertrophic adipocytes that are associated with increased adipose tissue mass 
are not always associated with metabolic dysfunction.  
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The importance of adipogenesis in metabolic health is demonstrated by the fact that 
impaired adipocyte differentiation is often associated with insulin resistance and metabolic disease 
states [37]. Indeed, the thiazolidenediones (TZDs), a class of PPARg agonists which act by 
enhancing adipogenesis are known to have potent insulin-sensitizing effects [38,39]. To fully 
understand how adipocytes contribute to metabolic dysfunction, it is necessary to understand the 
development of adipocytes. Adipogenesis is a tightly regulated cellular process by which 
adipocytes are developed from adipocyte precursor cells, or preadipocytes, via cellular 
differentiation. This process is driven by peroxisome proliferator-activated receptor g (PPARg ), 
the master regulator of adipogenesis, in conjunction with sterol regulatory element-binding 
transcription factor 1c (SREBP1c) to enhance the expression of lipogenic genes [6,40]. 
Adipogenesis is transcriptionally regulated by PPARg, which is required and is the principal 
regulator of adipogenesis both in vivo and in vitro [28,41]. PPARg has also been reported to induce 
the expression of signal transducers and activators of transcription 5A and B (STAT5A and B), 
which further promote adipogenesis [42,43]. In addition, CCAAT/enhancer-binding proteins 
(C/EBPs) are transcription factors that regulate proliferation and differentiation, and C/EBP α, β 
and δ have been  shown to be regulators of adipogenesis [44]. Moreover, C/EBPβ and C/EBPδ 
work in conjunction during early stages of adipogenesis to induce expression of C/EBPα and 
PPARg to promote adipocyte differentiation [28]. Although many transcriptional factors have been 
identified as regulators of adipogenesis, other proteins are likely to directly or indirectly regulate 
adipogenesis. 
1.2 Mitochondrial Pyruvate Carriers 
Pyruvate is an essential metabolite, and transport of pyruvate into the mitochondria is vital 
for metabolic processes such as glycolysis [45]. Cellular pyruvate can be reduced to lactate by 
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lactate dehydrogenase (LDH) to generate nicotinamide adenine dinucleotide (NAD+), which is 
required for glycolysis to produce ATP, or it can be transported into the mitochondrial matrix 
where it is oxidized to acetyl CoA by the pyruvate dehydrogenase complex (PDC) before entering 
into the TCA cycle [45]. Mitochondrial pyruvate carriers (MPCs) are transmembrane proteins 
located on the inner mitochondrial membrane that transport pyruvate from the cytosol into the 
mitochondrial matrix [46]. In 1970, a mitochondrial pyruvate transporter was first identified in rat 
liver and described as a translocator that couples hydroxy ion counterflux to proton symport to 
transport pyruvate across the mitochondrial matrix [47]. Although the mitochondrial pyruvate 
transporter was discovered in 1970, it wasn’t until 2012 that MPC proteins were characterized 
[48].  Bricker et. al. identified two MPC isoforms, MPC1 and MPC2 (also known as Brp44L and 
Brp44, respectively), that form a heterodimer to actively transport pyruvate into the inner 
mitochondrial membrane in mammals and Drosophila [46,48]. While there are only two isoforms 
in mammals and flies, three isoforms have been found in Saccharomyces cerevisiae: MPC1, 
MPC2, and MPC3 [48]. In humans and flies, MPC1 and MPC2 act in a codependent manner, as 
the loss or deletion of one protein results in the loss of the other MPC due to destabilization of the 
MPC1:MCP2 complex [48–50]. The use of  MPC1 mutants demonstrated that the dimerization of 
MPC1 and MPC2  in the inner mitochondrial membrane is essential for pyruvate uptake into the 
mitochondria of Saccharomyces cerevisiae for generation of acetyl CoA [48].  
MPC1 expression may also play a role in cancer metabolism. An increase in the rate of 
glycolysis is one of the distinct metabolic features present in cancer cells, along with mitochondrial 
reprogramming and a down regulation of lipid metabolism [51]. The Warburg effect, characterized 
by a decrease in pyruvate oxidation, is one of the hallmarks of the metabolic reprogramming in 
cancer cells [52]. Schell et. al. have implicated the reduced expression of MPCs as a culprit in 
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cancer cell development via its involvement in the Warburg effect [52]. The MPC1 locus, but not 
MPC2 locus, was found to be within a region that is frequently deleted in cancer, resulting in very 
low expression of MPC1 in cancer cells [52]. In human gastric cancer (GC) tissue and cells, MPC1 
expression was significantly downregulated and was associated with advanced tumor node 
metastasis (TNM) [53]. In addition, reintroduction of MPC1 into colon cancer cell lines via 
retroviral expression resulted in stabilization of the MPC complex and enhanced pyruvate 
oxidation to inhibit cell proliferation [52]. These lines of evidence suggest that MPCs could be 
targets for cancer therapeutics. 
Much is known about pyruvate transport in the heart. Shearman et. al. discovered that 
MPCs were expressed in the heart, and showed that MPCs were as abundant in the heart as in the 
liver [54]. MPC2 deficiency in heart mitochondria of C57BL6 mice resulted in reduced pyruvate 
utilization and pyruvate/malate-stimulated respiration [55]. Reduced pyruvate oxidation and 
mitochondrial metabolism have been witnessed in chronic heart failure [56–59] and have been 
suspected to be due to reductions in PDH activity [60]. Collectively, these studies suggest that 
enhancement of MPC import could potentially improve cardiac function.  
Panic et. al. reported that the loss of MPC1 in BAT of C57BL6 mice resulted in impaired 
thermogenesis and increased sensitivity to cold exposure [61]. In addition, a BAT-specific deletion 
of MPC1 reduced core body temperature and impaired glucose metabolism [61]. In a liver-specific 
MPC2 knockout mouse model, the loss of MPC2 impaired pyruvate oxidation for generation of 
tricarboxylic acid (TCA) cycle intermediates and glucose [49]. Hepatic gluconeogenesis is 
enhanced in the event of insulin deficiency and contributes to hyperglycemia associated with 
diabetes [49]. Thus, MPC2 may contribute to diabetes via its role in hepatic glucose output.  
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Although data pertaining to the functions of MPCs are abundant, very little is known about their 
regulation and roles in adipocytes. 
1.3 Lysine Acetyltransferase 8 (KAT8) 
Histone acetyltransferases (HATs) are responsible for transferring acetyl groups from 
acetyl CoA to specific lysine residues on their target substrates, that are often histones. Histone 
acetylation, which modulates chromatin structure and gene expression, is primarily controlled by 
HATs and reversed by histone deacetylases (HDACs). However, HATs can acetylate other 
proteins besides histones and are now more commonly referred to as lysine acetyltransferases, or 
KATs. One member of the KAT family, KAT8 has been reported to play a role in many cellular 
functions. 
KAT8 was initially described as males-absent-on-the-first (MOF) in Drosophila 
melanogaster, because it is a male-specific protein that exhibits lethality when mutated in males 
[62]. In Drosophila, KAT8 contributes to two regulatory complexes that both play roles in 
activation of target gene transcription. The first is the male-specific lethal (MSL) complex, which 
is a chromatin remodeling complex assembled only in male flies [63]. This complex consists of 
KAT8 alongside four other core components: MSL1, MSL2, MSL3 and MLE (maleless helicase) 
as well as two long non-coding RNAs on the X chromosome (roX1 and roX2) [64]. The second, 
non-specific lethal (NSL) complex, is present in both males and females and modulates  
transcription of housekeeping genes [63]. This complex consists of KAT8 and five other core 
components: NSL1, NSL2, NSL3, methyl binding domain-related 2 (MBDR2) and microspherule 
protein 2 (MCRS2) [62]. In each of the mammalian species in which KAT8 is present, the MSL 
complex is conserved [63].  
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KAT8 is also a member of the MYST family, named for its original members MOZ, 
Ybf2/Sas3, Sas2, and Tip60 [65]. The MYST family proteins are characterized by their roles in 
post-translational modifications of histone and chromatin remodeling in eukaryotes [66]. Proteins 
in the MYST group all possess the conserved MYST domain, which consists of an acetyl CoA-
binding motif as well as a CCHC-type zinc finger to mediate substrate recognition [66]. Functional 
domains also present in KAT8 include a N-terminal chromodomain (CHD) which plays a role in 
RNA binding [67,68], a HAT domain, and a chromobarrel domain (CBD) at the C-terminal which 
modulates HAT activity [62,63]. The N-terminal domains are responsible for the modulation of 
substrate binding [62]. KAT8 has been reported to have many functions and interactions with a 
variety of substrates [69–78].  
One of KAT8’s well-studied targets in mammalian cells is Histone 4 Lysine 16 (H4K16), 
via the MSL complex or NSL complex [69]. KAT8 can also acetylate H4K5 and H4K8 via the 
NSL complex [69]. Many studies have shown that disruption of KAT8 expression and function 
can result in irregularities in cell cycle, cell proliferation, gene transcription, DNA damage repair, 
early embryonic development, or promotion of tumorigenesis, and autophagy [69,70,77–79]. 
Although histones are the primary targets for KAT8 activity, KAT8 has been shown to acetylate 
other substrates. Acetylation of LSD1 (lysine-specific histone demethylase 1) by KAT8 reduced 
tumorigenesis [71], while KAT8-mediated acetylation of  the tumor suppressor p53 has been 
reported to promote cellular apoptosis in response to DNA damage [72–74]. Another study showed 
that KAT8 acetylates DBC1 (deleted in breast cancer 1) and reduces DBC1’s binding affinity for 
SIRT1 (sirtuin 1), a histone deacetylase, to increase SIRT1 activity [75].  
In mouse embryonic fibroblast (MEF) cells, it was reported that an induction of autophagy 
by amino acid starvation resulted in reduced H4K16 acetylation via the downregulation of KAT8 
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[80]. This same study showed that rapamycin treatments in autophagic impaired cells could elicit 
the same downregulation of H4K16 acetylation in both MEF and HeLa cells [80]. Sheikh et. al. 
developed a tamoxifen-inducible KAT8 knockout in MEFs, in which the loss of KAT8 expectedly 
resulted in diminished H4K16 acetylation [81]. Loss of KAT8 resulted in an arrest in cellular 
proliferation, and the expression of genes associated with the progression of the cell cycle was 
blunted [81]. Loss of KAT8 in podocytes significantly downregulated pathways associated with 
lysosomes, valine, leucine, and isoleucine degradation, endocytosis, and extracellular matrix-
receptor interactions [81]. KAT8-deficient MEFs treated with adriamycin to induce autophagy 
revealed the same pathway inhibitions [81]. Overall, these studies show that KAT8 plays a role in 
cellular autophagy. 
Recently, another study reports that acetylation of interferon regulatory factor 3 (IRF3) by 
KAT8 suppresses antiviral innate immunity [82]. This finding is interesting because activation of 
IRF3 is tightly regulated by posttranslational modifications such as phosphorylation and 
ubiquitination. Phosphorylation positively regulates IRF3 activation while ubiquitination results 
in degradation of IRF3. The knockdown of KAT8 in peritoneal macrophages treated with vesicular 
stomatitis virus (VSV) selectively induces the expression of type I interferons (IFNs), IFNa and 
IFNb [82]. KAT8-deficient mice infected with VSV also had reduced mortality rates compared 
with the KAT8-sufficient mice, due to the induction of type I IFNs [82]. Immunoprecipitation 
studies in HEK293T cells revealed that KAT8 suppresses type I IFN production via its direct 
interaction with IRF3, which was enhanced after VSV infection. Not only does KAT8 interact 
with IRF3, it promotes IRF3 acetylation at K359 without affecting IRF3 activation [82]. Overall, 
this study shows that IRF3 acetylation by KAT8 regulates type-I IFN production and is enhanced 
during viral infection. 
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Fatty Acid Synthase (FASN), which drives fatty acid synthesis and de novo lipogenesis, has 
been reported as a target of KAT8. A study conducted by Lin et al. confirmed the interaction of 
KAT8 and FASN through a series of studies in HEK293T and HCT116 cells (human colorectal 
cancer line) to examine FASN acetylation [76]. Immunoprecipitation experiments were performed 
to screen various KAT enzymes for interaction with FAS, and KAT8 was the only one found to 
immunoprecipitate with FAS, indicating a direct interaction between the two proteins [76]. In 
addition, overexpression of KAT8 produced a robust decline in FASN, suggesting that KAT8 
directly interacts with FASN and promotes its degradation via acetylation [76]. 
Gao et al. have reported that STAT5B modulates KAT8 expression binding to the MOF 
promoter in 3T3-L1 cells and that this interaction was necessary to negatively regulate 
adipogenesis [83]. However, there are no other studies of KAT8 in adipocytes. Interestingly, 
however, a genome-wide association study (GWAS) meta-analysis identified KAT8 as 1 of 97 
body mass index (BMI)-associated loci that contribute to variations in BMI [84]. The discovery of 
a role for KAT8 in fat cells would be a novel finding and would enhance the field of adipocyte 
biology.  
The incidence of obesity and related metabolic diseases continues to rise around the world and 
represents one of the greatest public health challenges of our time. It is now known that adipose 
tissue has a very important role in metabolic health, and that disruption of adipocyte development 
and function can drive poor metabolic outcomes in obese and insulin resistant states. Pursuing a 
greater understanding of adipocyte biology is crucial to stemming the tide of metabolic dysfunction 
in obesity. Studying the functions of both KAT8 and MPCs in adipocyte development and function 
can provide insight into the complexity of this endocrine organ.  
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CHAPTER 2. MITOCHONDRIAL PYRUVATE CARRIERS ARE NOT 
REQUIRED FOR ADIPOGENESIS, BUT REGULATED BY HIGH-FAT 
FEEDING IN BROWN ADIPOSE TISSUE1 
 
2.1 Introduction 
The mitochondrial pyruvate carriers (MPCs) are transmembrane proteins, found on the 
inner mitochondrial membrane, that transport pyruvate from the cytosol into the mitochondrial 
matrix where pyruvate is oxidized to acetyl CoA and carbon dioxide via the pyruvate 
dehydrogenase complex (PDC). Acetyl CoA is utilized in the citric acid cycle to form NADH for 
oxidative phosphorylation (OXPHOS) to create a proton gradient for the production of ATP via 
the ATP synthase complex. There are two MPC proteins in mammals (MPC1 and MPC2), but 
there are three that have been identified in Saccharomyces cerevisiae (MPC1, MPC2, and MPC3) 
[45]. In mammals, MPC1 and 2 form a heterodimer to actively transport pyruvate into the 
mitochondria [85]. Since MPC1 and MPC2 act in a codependent manner, the loss or deletion of 
one of these proteins results in the loss of the other MPC due to destabilization [85–87]. The study 
of MPC1 mutants has confirmed that dimerization of MPC1 and MPC2 in the inner mitochondrial 
membrane is essential for pyruvate uptake into the mitochondria [86].  
MPC1 expression may also play a role in cancer metabolism as inhibition of MPC complex 
formation, via UK-5099, hinders pyruvate’s entry into the mitochondria and is associated with 
increased glycolysis [88]. Increased glycolysis is a distinct metabolic feature of cancer cells, along 
with mitochondrial reprogramming and decreased lipid metabolism [51]. The MPC inhibitor, 2-
Cyano-3-(1-phenyl-1H-inodl-3-yl)-2-propenic acid (UK-5099), binds to MPCs, which deactivates 
 
This chapter previously appeared as: Burrell J.A., Richard A.J., King W.T., Stephens J.M. (2019). Mitochondrial 
Pyruvate Carriers are not Required for Adipogenesis but are Regulated by High‐Fat Feeding in Brown Adipose 
Tissue. Obesity. 28(2):293-302. doi: 10.1002/oby.22678. It is reprinted by permission of John Wiley and Sons. 
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the MPC complex and inhibits pyruvate oxidation [89]. Thiazolidinediones (TZDs) inhibit MPC 
in several cell types, and in skeletal muscle inhibition of MPC is associated with increased glucose 
uptake and increased insulin sensitivity. Using the CRISPR/Cas9 system, a heterozygous MPC1 
knockdown model was generated and these mice had reduced lipid accumulation, increased 
lipolysis, enhanced fatty acid oxidation, and decreased energy expenditure [90]. During 
adipogenesis, mitochondrial density is increased by 20- to 30- fold along with increases in 
mitochondrial gene expression and oxidative capacity to meet increasing energy requirements [91–
95]. Insufficient or reduced mitochondrial density in tissues with a high energy demand like the 
brain, heart, muscles, and endocrine organs, such as adipose tissue, are associated with disease 
states [96]. Although MPCs have been studied in several cell and tissue types, the role of these 
proteins in adipocyte development and their regulation in conditions of obesity is not known.  
In our novel studies, we examined the requirement of MPC1 during adipocyte development 
using two independent approaches. Both pharmacological inhibition of MPCs as well as siRNA-
mediated knockdown of MPC1 demonstrated that the expression and/or activity of MPC1 was not 
required for adipogenesis in 3T3-L1 cells. To our knowledge, this is the first siRNA-mediated 
MPC1 knockdown reported in 3T3-L1 cells. However, siRNA-mediated knockdown of MPC1 and 
MPC2 in 832/13 β-cells resulted in impaired insulin secretion in response to glucose and 
reductions in glucose-stimulated oxygen consumption [97]. We also examined the modulation of 
MPC expression in both brown and white adipose tissue depots of male and female mice in a 
rodent model of diet-induced obesity. Expression levels of MPC1 and MPC2 were substantially 
decreased in the brown adipose tissue (BAT) of male mice following high-fat feeding, but not in 
female mice under the same conditions. In conclusion, our results indicate that loss of MPC1 does 
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not have any effect on adipogenesis of 3T3-L1 preadipocytes; MPC1 and 2 are highly expressed 
in BAT; and MPC1 and 2 are modulated by high-fat feeding in BAT of male mice. 
 
 
2.2 Materials and Methods 
Animals and Diets- Four-week-old male and female C57BL/6J mice were purchased from 
Jackson Laboratories (Stock #000664; Bar Harbor, ME). Animals were housed in a temperature 
(22 ± 2°C)- and humidity-controlled (45–55%) room under a 12-h light/dark cycle. At six weeks 
of age, mice were placed on respective diets. Mice were allowed ad libitum access to food and 
water. For twelve weeks, mice had access to either LFD containing 20% kcal protein, 70% kcal 
carbohydrate, and 10% kcal fat (D12450J; Research Diets, Inc. New Brunswick, NJ) or HFD 
containing 20% kcal protein, 20% kcal carbohydrate, and 60% kcal fat (D12492; Research Diets, 
Inc. New Brunswick, NJ). Body weights were obtained biweekly. Mice were fasted for four hours 
prior to sacrifice. All animal studies were performed with approval from the Pennington 
Biomedical Research Center Institutional Animal Care and Use Committee. 
Animal body composition and glucose tolerance measurements- Non-fasting body 
composition was measured by NMR (Bruckner Minispec) before beginning LF or HF diet 
intervention at 6 weeks of age and at 19 weeks of age (after 12 weeks of LFD- or HFD-feeding). 
Adiposity was calculated as total fat mass/total body weight x 100. Following a 4-hour fast, 
intraperitoneal glucose tolerance tests (IPGTTs) were performed on all animals at 17 weeks of age 
(10 weeks on diet). A baseline blood glucose measurement was obtained via tail nick (0 minutes), 
and animals were then injected with 2.5g/kg glucose. Blood glucose measurements were obtained 
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via a drop of blood collected from the tail vein at 20, 40, 60, and 120 minutes post-injection. Blood 
glucose measurements were performed using a Breeze 2 glucometer (Bayer, Parsippany, NJ). 
Cell culture- Murine 3T3-L1 preadipocytes were grown in Dulbecco’s Modified Eagle’s Media 
(DMEM) (Sigma-Aldrich, St. Louis, MO) with 10% bovine calf serum. Two days after confluence, 
the preadipocytes were induced to differentiate using a standard protocol and induction cocktail 
composed of 3-isobutyl-methylxanthine, dexamethasone, insulin (MDI), and 10% characterized 
fetal bovine serum (FBS) in DMEM. HyClone calf and fetal bovine serum were purchased from 
Thermo Scientific (Waltham, MA) or GE Healthcare Life Sciences (Marlborough, MA). The 
medium was changed every 48 – 72 hours during growth and differentiation.  
Pharmacological Inhibitor (UK-5099) Treatments- 3T3-L1 preadipocytes were trypsinized and 
seeded into 6-well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free 10% bovine 
calf/DMEM when approximately 70% confluent in 10-cm plates. 3T3-L1 preadipocytes were 
treated with 10µM UK-5099 (Sigma-Aldrich, St. Louis MO; PZ0160) added to the medium upon 
seeding. Preadipocytes were induced to differentiate as described above. Cells were fed with 
antibiotic-free media and treated with UK-5099 every 48 hours. Seven days after the induction of 
differentiation, the cell monolayers were harvested for protein in immunoprecipitation (IP) buffer 
containing 10mM Tris (pH 7.4), 150mM NaCl, 1mM EGTA, 1mM EDTA, 1% Triton X-100, 0.5% 
IGEPAL CA-630, protease inhibitors (1mM phenylmethylsulfonyl fluoride, 1μM pepstatin, 50 
trypsin inhibitory milliunits of aprotinin, 10μM leupeptin, 1 mM 1,10-phenanthroline), and 
phosphatase inhibitors (0.2mM sodium vanadate and 100µM sodium fluoride), and for RNA in 
buffer provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown 
efficiency. Three biological and technical replicates and were analyzed for each dose.  
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Cytotoxicity and cell viability assays- The ToxiLight BioAssay kit (Lonza, Cologne, Germany) 
was utilized according to the manufacturer’s protocol. ToxiLight 100% lysis reagent (Lonza, 
Cologne, Germany) was utilized as a positive control. Cell viability was assessed by counting 
trypan blue-stained cells using a hemocytometer. 
Whole cell extract preparation- Cell monolayers were rinsed once with phosphate-buffered 
saline (PBS) and then scraped into non-denaturing IP buffer. The whole cell extracts were stored 
at -80°C before being thawed and passed through a 20-gauge needle five times. The whole cell 
extract was clarified via centrifugation at 13,000 x g for 10 min at 4°C. 
Small interfering RNA (siRNA)-mediated knockdown- 3T3-L1 preadipocytes were trypsinized 
and re-plated in 6-well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free 10% bovine 
calf/DMEM when approximately 70% confluent in 10-cm plates. Using the protocol from 
Dharmacon, preadipocytes were transfected with 33nM siRNA (Dharmacon, Lafayette, CO; Non-
targeting siRNA Cat #: D-001810-10-50, siRNA targeting MPC1 Cat #: L-040908-01-0005) and 
the DharmaFECT Duo transfection reagent (Dharmacon, Lafayette, CO, Cat #: T-2010-03) in 
OptiMEM reduced serum medium (Thermo Fisher, Waltham, MA; Cat #: 31985088). Non-
targeting siRNA was used as negative control. Cells were treated with the siRNA cocktail during 
initial plating and grown to confluence. Two days after confluence, cells were induced to 
differentiate with the MDI-induction cocktail, as described above, and transfected again with the 
siRNA cocktail. After 48 hours, the cells were treated with ¼ normal dose of insulin and 
transfected once again with the siRNA cocktail.  Cells were fed every 48 hours with antibiotic-
free media throughout the entire knockdown process. Seven days after the induction of 
differentiation, the cell monolayers were harvested for protein in IP buffer, and for RNA in buffer 
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provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown efficiency. 
Three biological and technical replicates were analyzed for each dose. 
Respirometry- Mitochondrial function was assessed by respirometry of intact cells using a 
Seahorse XFe24 Analyzer (Agilent Technologies; Santa Clara, CA). Mature 3T3-L1 adipocytes 
were seeded at 1.0x105 cells per well in an XF24 specialized cell culture microplate that was coated 
with 0.1% gelatin for 48 hours prior to seeding. Upon seeding, cells were incubated at 37°C 
without CO2 for one hour prior to assay in XF base media (Agilent Technologies; Santa Clara, 
CA) supplemented with 25mM glucose and 2mM L-glutamine at pH 7.4. After basal oxygen 
consumption was measured for three cycles, 1mM sodium pyruvate ± 10µM UK-5099 was 
injected into each well. After three basal measurement cycles, 1µM oligomycin, 600nM carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and 5µM rotenone/antimycin A were 
serially injected, and oxygen consumption was measured for three, six, and three cycles, 
respectively. After the assay was complete, cells were harvested in RIPA buffer, and protein 
concentration was quantified using the bicinchoninic acid (BCA) assay kit (Sigma-Aldrich, St. 
Louis, MO; Cat #: BCA1). Oxygen consumption rate was normalized to µg of protein. 
Gel electrophoresis and immunoblotting- Protein content of cell extracts was quantified via 
BCA assay. Samples were separated on 7.5%, 12%, or 15% sodium dodecyl sulfate (SDS) 
polyacrylamide (PA) gels (acrylamide; National Diagnostics, Atlanta, GA; Cat #: EC-890) and 
transferred to nitrocellulose membranes (BioRad, Hercules, CA; Cat #: 162-0115) in 25 mM Tris, 
192 mM glycine, and 20% methanol. After the transfer, membrane strips were blocked in 4% non-
fat milk for 1 hour at room temperature and washed with TBS-T before incubating with primary 
antibodies overnight at 4°C. Strips were washed with TBS-T and then incubated with either anti-
mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Jackson 
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ImmunoResearch, West Grove, PA) for 1h. Strips were washed with TBS-T and visualized with 
enhanced chemiluminescence (Pierce/Thermo Scientific, Waltham, MA).  
Antibodies- Anti-STAT5A (L-20; sc-1081; rabbit polyclonal), anti-adipsin (M-120; sc-50419; 
rabbit polyclonal), anti-STAT3 (C-20; sc-482; rabbit polyclonal) and anti-ERK1/2 (C-16; sc-93; 
rabbit polyclonal) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX). Anti-
adiponectin (PA1-054; rabbit polyclonal) antibody was purchased from Thermo Scientific 
(Waltham, MA). Anti-MPC1 (14462S; rabbit monoclonal) and anti-MPC2 (D4I7G; rabbit 
monoclonal) antibodies were purchased from Cell Signaling Technology (Danvers, MA).  
RNA analysis- Total RNA from tissue samples was extracted according to TRIzol manufacturer 
instructions. RNA from tissue or adipocyte monolayers was purified using the RNeasy mini kit 
(Qiagen, Hilden, Germany). Ten microliters of purified RNA were used for reverse transcription 
(RT) to generate cDNA according to the Applied Biosystems protocol (Applied Biosystems, Foster 
City, CA; Cat #: 4368813). cDNA was quantified using the real-time quantitative PCR (qPCR) 
method in a total volume of 10µL (2µL DNA and 8µL reaction master mix) using an Applied 
Biosystems 7900HT System with SDS 2.4 software. qPCR was performed using Takara SYBR 
premix (Takara Bio USA Inc., Madison, WI, USA) and primers from IDT (Integrated DNA 
Technologies, Skokie, IL, USA). Thermal cycling conditions were as follows 2 min at 50 °C, 10 
min at 95 °C, 40 cycles of 15 s at 95 °C; dissociation stage 15 s at 95 °C, 15 s at 60 °C, and 15 s 
at 95 °C. Cyclophilin A (Ppia) and Non-POU domain containing octamer binding protein (NoNo) 
were used as reference genes. The following mouse genes were examined by RT-qPCR: 
Oxoglutarate Dehydrogenase (Ogdh), Succinate Dehydrogenase Complex Iron Sulfur Subunit B 
(Sdhb), Mitochondrial Pyruvate Carrier 1 (Mpc1), Mpc2, CCAAT enhancer-binding protein alpha 
(Cebpa), Peroxisome Proliferator-Activated Receptor Gamma (Pparg), Adiponectin (Adpn), 
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Citrate synthase (Cs), Fatty Acid Binding Protein 4 (aP2), Fatty Acid Synthase (Fas), and Adipsin 
(Cfd). Primer sequences are shown in Table 1.  
Lipid Accumulation Measurement- Seven days after the induction of differentiation, cells were 
fixed and stained with Oil Red O (ORO; Sigma-Aldrich, St. Louis, MO, USA) as described 
previously [98].  
Statistical analysis- Statistical analyses were performed using GraphPad Prism software (version 
8; La Jolla, CA, USA). Differences between groups were calculated using Student’s t-tests and 
two-way ANOVA. Area under the curve (AUC) calculations and standard linear regression 
analyses were performed to determine correlations between MPC protein expression and adiposity 
or GTT AUC. Results from studies of cultured adipocytes are shown as mean ± standard error of 
the mean (SEM). Results were considered statistically significant when p < 0.05.  
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Table 2.1. qPCR Primer Sequences 


































































2.3.1  Loss of MPC1 has no effect on in vitro adipogenesis 
Prior to determining the potential requirement for MPC1 expression for adipocyte 
differentiation, we examined the protein expression of MPC1 and MPC2 over a seven-day 
adipogenesis timecourse in 3T3-L1 cells. As shown in Figure 2.1, both MPC1 and MPC2 protein 
expressions were highly induced during differentiation. The increased expression was apparent 
four days after the induction of adipogenesis (Figure 2.1A and 2.1B). To assess the requirement 
of MPCs on adipogenesis, we used a potent pharmacological inhibitor of MPCs, UK-5099, which 
acts by binding to MPCs and modifying a thiol group to prevent the formation of the MPC1 and 
MPC2 heterodimer, thus reducing pyruvate transport into the mitochondrial matrix [99,100]. 
Preadipocytes were induced to differentiate in the presence of UK-5099 at various doses. As shown 
in Figure 2.2, a range of inhibitor doses did not inhibit adipocyte differentiation as judged by lipid 
accumulation with Oil Red O staining (Figure 2.2A) or adipocyte marker gene expression (Figure 
2.2B). Three adipogenic markers (adiponectin, aP2, and FAS) were examined to demonstrate 
adipocyte development.  
To examine the efficacy of UK-5099, respirometry experiments were performed on 3T3-
L1 cells to measure oxygen consumption in the presence of pyruvate with or without the addition 
of the inhibitor. There were no differences in oxygen consumption observed during baseline 
readings after the addition of pyruvate ± UK-5099, or oligomycin. After the addition of FCCP, the 
maximal oxygen consumption rates in 3T3-L1 cells treated with the inhibitor were significantly 
reduced in comparison to the control (1.167 vs. 3.411pmol/min/µg protein) (Figure 2.2C and 
2.2D). Oxygen consumption rates were reduced by UK-5099 in the presence of the mitochondrial 
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uncoupler, FCCP, likely due to a reduction of pyruvate substrate entry into the mitochondria. Cell 
viability and cytotoxicity assays show that UK-5099-treated 3T3-L1 cells had no changes in 
cytotoxicity (Figure 2.2E) or cell viability (Figure 2.2F) in comparison to DMSO, which indicates 
that UK-5099 had no toxic effects on the cells. 
An independent approach using siRNA-mediated knockdowns of MPC1 was also 
performed to examine the role of MPCs on adipogenesis in 3T3-L1 cells. Despite substantial loss 
of MPC1 protein expression (Figure 2.3A and 2.3B), there were no observed changes in 
adiponectin protein expression or lipid accumulation (Figure 2.3A and 2.3C). Though Mpc1 gene 
expression was significantly reduced, mRNA expression of Mpc2 and adipogenic markers, such 
as Adpn, Ap2, and Pparg were not affected (Figure 2.3D). Although Cebpa gene expression 
increased in the absence of MPC1, this increase did not affect adipogenesis. These data confirm 
that loss of MPC1 expression does not have any significant effects on adipogenesis of 3T3-L1 
cells. 
 
Figure 2.1. MPC1 and MPC2 expression is induced during adipogenesis in 3T3-L1 cells. 3T3-L1 
adipocytes were induced to differentiate using the MDI cocktail, and whole cell extracts were 
harvested at the indicated time points to assess MPC1 protein expression over a timecourse of 
adipocyte differentiation. A) Whole cell extracts (75 µg of protein per lane) were subjected Western 
blot analysis. Adiponectin was utilized as a positive control for adipogenesis. B) Densitometry 
quantification of MPC1 and MPC2 band intensities at the indicated time points. MPC1 and 2 band 
intensities were normalized to ERK 1/2. (n = 3 pooled 10-cm plates per time point). Experiments 




Figure 2.2. UK-5099, a pharmacological inhibitor of MPC1, does not inhibit adipogenesis of 3T3-
L1 cells. A and B) 3T3-L1 preadipocytes were induced to differentiate either untreated or treated 
with DMSO vehicle or indicated dose of UK-5099 at the time of induction and every 2 days during 
differentiation. A) Seven days post-induction, cells were fixed and stained with Oil Red O. 
Photographs are from the same experiment, and wells (n = 3 wells per treatment) were treated at 
the same time. B) Seven days post-induction, RNA was isolated, purified and subjected to RT-
qPCR to measure gene expression of Mpc1, adipogenic markers [adiponectin (Adpn), adipocyte 
lipid binding protein (Ap2), and fatty acid synthase (Fas)], and the mitochondrial marker, citrate 
synthase (Cs) (n = 3 wells per treatment). Target gene expression was normalized to the reference 
gene, Nono, and data are plotted as fold change over the DMSO control. C and D) Respirometry 
experiments were performed to demonstrate the efficacy of the MPC1 inhibitor in mature 3T3-L1 
adipocytes. After introducing 1mM pyruvate ± 10µM UK-5099, the oxygen consumption rate 
(OCR) was measured using a Seahorse XF analyzer for 3 cycles prior to performing the 
Mitochondrial Stress Test using 1 µM Oligomycin (Oligo), 600 nM FCCP (carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone) and 5 µM Rotenone (Rot)/ Antimycin A (AA). C) Full 
respiration profile showing the mean OCR normalized by the protein content ± SEM for each well 
(n = 10 wells per treatment). D) Maximal respiration after the addition of 600 nM FCCP is shown 
(n = 10 wells per treatment). Data shown are mean oxygen consumption rates of cells treated with 
pyruvate (P) or pyruvate and UK-5099 (P+I). Panels C and D were analyzed by unpaired t-test. 
**** indicates p < 0.0001 vs. pyruvate control. Experiments were repeated at least twice on 
independent batches of cells. E and F) Seven days post-induction, UK-5099 treated 3T3-L1 cells 
were either subjected to cytotoxicity assay (E) via ToxiLight BioAssay kit or stained with trypan 
blue and counted to assess cell viability (F) at indicated doses (n = 3 wells per treatment for a 
single batch of cells).  
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Figure 2.3. Knockdown of MPC1 gene expression with siRNA does not inhibit adipogenesis of 
3T3-L1 cells. 3T3-L1 preadipocytes were transfected with non-targeting siRNA (NT) or MPC1 
siRNA upon plating and every 48 hours following induction of differentiation with MDI cocktail 
until endpoint assessments protein and gene expression as well as Oil Red O staining) were 
conducted on the cells at seven days post-MDI. A) Whole cell extracts were isolated and 50 µg 
protein per lane were analyzed by Western blot analysis (n = 3 replicate wells per treatment). 
Adiponectin was utilized as a differentiated adipocyte marker. B) MPC1 band intensities were 
quantified by densitometry and normalized to ERK 1/2 for each treatment. C) The cells were fixed 
and stained with Oil Red O to examine lipid accumulation. D) RNA was isolated, purified and 
subjected to RT-qPCR to show gene expression of Mpc1, Mpc2, adipogenic markers [adiponectin 
(Adpn), adipocyte lipid binding protein (Ap2), CCAAT enhancer-binding protein alpha (Cebpa) 
and peroxisome proliferator-activated receptor gamma (Pparg)], and mitochondrial markers 
[citrate synthase (Cs), oxoglutarate dehydrogenase (Ogdh) and succinate dehydrogenase (Sdhb)]. 
Data was analyzed by two-way ANOVA. * indicates p < 0.05, ** indicates p < 0.01, and *** 
indicates p < 0.001 vs. NT control (n = 3 wells per treatment). 
2.3.2  MPCs are regulated in the adipose tissue of mice during high-fat feeding 
To further study MPCs, we examined MPC1 and MPC2 protein expression in several 
adipose tissue depots and compared its expression with other tissues in mice. As shown in Figure 
2.4, MPC1 and MPC2 were highly expressed in brown-adipose tissue (BAT), heart, liver and 
kidneys in C57BL/6J mice. When directly compared, it was apparent that there are differences in 
protein expression of MPC1 and MPC2 in some tissues. MPC1 had a much higher protein 
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expression than MPC2 in the skeletal muscle, both the extensor digitorum longus (EDL) and the 
gastrocnemius (Gastroc), and in the brain (Figure 2.4). Also, the levels of MPC1 and MPC2 
expression were low in all of the white adipose tissue (WAT) depots (Figure 2.4).   
To determine if MPC expression was regulated by diet-induced obesity, mice were placed 
on either low-fat (LF) or high-fat (HF) diets for 12 weeks. BAT, inguinal WAT (iWAT), and 
gonadal/epididymal WAT (gWAT) were harvested and analyzed in both male and female mice on 
LF or HF diets. In both male and female mice, Mpc1 mRNA expression was significantly 
decreased in the BAT, iWAT, and gWAT during high-fat feeding of male and female mice while 
Mpc2 mRNA expression was decreased in the gWAT of males and the BAT and gWAT of females 
during high-fat feeding (Figure 2.5). We also observed an expected decrease in fatty acid synthase 
(Fas) gene expression during high-fat feeding [101]. Protein expression of both MPC1 and MPC2 
in BAT was significantly reduced in male mice on HF diets (Figure 2.6A and 2.6B). This 
significant decline in MPC1 and MPC2 levels was not observed in the female mice fed a HF diets 
(Figure 2.6C and 2.6D). In iWAT, MPC1 protein expression was extremely low, near the detection 
limit, and no changes in protein levels were observed as a result of HFD-feeding (data not shown). 
These data indicate that MPC gene expression is downregulated in a depot and sex specific manner 
by high-fat feeding.  
Because female C57BL/6 mice are typically less susceptible to metabolic dysfunction 
during HF diet-induced obesity than their male counterparts [102–104], we examined the 
relationships between MPC1 or MPC2 protein expression and adiposity or glucose tolerance. 
Protein expression of MPC1 and MPC2 for males significantly correlates with adiposity and 
glucose tolerance test (GTT) AUC for male, but not female mice (Figure 2,7). For the male mice, 
the linear fits of MPC1 or MPC2 versus adiposity or GTT AUC have an R2 value of greater than 
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0.5 and the slopes are significantly non-zero (p < 0.01), while female mice R2 values are less than 
0.4 and none of the slopes are significantly non-zero. These data show that decreased levels MPC 
proteins in male mice are associated with increased adiposity and decreased glucose tolerance. 
 
Figure 2.4. MPC1 and MPC2 proteins are highly expressed in brown adipose tissue, liver, and 
heart. Select tissues were harvested from a 27-week old C57BL/6J mouse to assess the tissue 
distribution of MPC1 and MPC2 proteins. A) Tissue samples were homogenized and 100 µg of 
total protein per lane were analyzed by Western blotting. B) MPC1 and MPC2 band intensities 
were quantified by densitometry and normalized to respective ERK 1/2 intensities for each tissue 
depot. gWAT, gonadal WAT; rpWAT, retroperitoneal WAT; iWAT, inguinal WAT; mWAT, 
mesenteric WAT; BAT, brown AT; EDL, extensor digitorum longus; gastroc, gastrocnemius.   
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Figure 2.5. Steady state mRNA expression of MPC1 is substantially decreased in adipose tissue 
after high-fat feeding in male and female C57BL/6J mice. Six-week old C57BL/6J mice were fed 
either a high-fat (HF) or low-fat (LF) diet for 12 weeks ad libitum before euthanizing and collecting 
tissue. BAT, iWAT, and gWAT samples were homogenized and RNA was isolated and purified 
from each tissue depot for male (A) and female (B) mice. Each sample was subjected to RT-qPCR 
to show gene expression of Mpc1, Mpc2, adipogenic markers (Adpn, Ap2, and Fas), adipokine 
(Adipsin), and mitochondrial marker (Cs). Data was analyzed by unpaired t-tests. * indicates p < 
0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001 vs.  LF diet (n 
= 6 per condition). Each sample was run in duplicate. Target gene expression was normalized to 
the reference gene, Cyclophilin A, and data are plotted as fold change over the LF control. 
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Figure 2.6. MPC1 and MPC2 expression is significantly decreased in the brown adipose tissue of 
male, but not female mice following high-fat feeding. Six-week old male and female C57BL/6J 
mice were fed either a high-fat (HF) or low-fat (LF) diet for 12 weeks ad libitum before euthanizing 
and collecting BAT. Tissue samples were homogenized, and 30 µg of total protein per lane were 
subjected to Western blot analysis (n = 6 per condition) for males (A) and females (C). MPC1 and 
MPC2 band intensities were quantified by densitometry and normalized to respective STAT3 
intensities for each sample; males (B) and females (D). Data was analyzed by two-way ANOVA.  
** indicates p < 0.01 vs. LF diet. 
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Figure 2.7.  Decreased MPC1 and MPC2 protein expression in BAT during DIO correlates with 
increased adiposity and decreased metabolic health in male, but not female, mice. A and B) MPC 
protein expression from the immunoblot quantification in Figure 6B and 6D was correlated with 
percent fat mass (adiposity) for male and female mice on LFD and HFD. Protein extracts were 
collected, and adiposity measured at 19 weeks of age (12 weeks on diet). C and D) MPC protein 
expression values for male and female mice were also plotted against area under the curve (AUC) 
of glucose tolerance tests (GTTs) performed on LFD and HFD-fed mice at 17 weeks of age (10 
weeks on diet) for male and female mice. Linear regression analyses were performed and are 
shown for data in A-D. R2 values indicate goodness of the linear fit for each data set, and whether 
the slope is significantly differently from zero is denoted by p value or ns (not significant). 
 
2.4 Discussion   
 Our novel data demonstrate the dispensability of MPC1 during adipogenesis in vitro as 
well as showing the expression and modulation of MPCs in brown adipose tissue in vivo during 
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diet-induced obesity (DIO). The observed increase in protein expressions of both MPC1 and 
MPC2 during adipocyte differentiation of 3T3-L1 cells (Figure 2.1) has not been previously 
reported in 3T3-L1 cells, but MPC1 and MPC2 expression is increased upon differentiation of 
LGR5+ intestinal stem cells (ISCs) [105]. The increase in MPC1 and 2 expressions in adipocytes 
is likely due to increased mitochondrial density and gene expression that occurs to generate energy 
needed to accommodate the enhanced metabolic requirements during adipogenesis [91,94,95]. 
Because of enhanced protein expression of MPCs during differentiation, we hypothesized that 
MPCs were necessary for the differentiation of 3T3-L1 cells.  
Contrary to our premise, two independent approaches using both pharmacological 
inhibition with UK-5099 (Figure 2.2) and siRNA-mediated knockdowns (Figure 2.3) of MPCs did 
not affect adipocyte development. Even at doses as low as 50nM, UK-5099 has been able to inhibit 
formation of the MPC1 and 2 heterodimer, thus inhibiting pyruvate transport via this complex 
[87,99]. In BAT progenitor cells, the addition of UK-5099 inhibited 13C-glucose incorporation into 
acetyl CoA [99] suggesting that the pyruvate produced from glycolysis of 13C-glucose was not 
utilized for acetyl CoA production due to impaired pyruvate uptake by the MPC heterodimer via 
UK-5099 inhibition. Liver-specific loss of MPC2 in C57BL/6J mice resulted in compromised, but 
not eliminated, pyruvate metabolism and suggested that mechanisms such as pyruvate-alanine 
cycling were activated to compensate for the loss of the MPC complex functionality [106]. A 
robust decline (~80%) in MPC1 expression via siRNA knockdowns also had no effect on adipocyte 
development (Figure 2.3). Our data further supports the current literature. Our observations 
suggest that although pyruvate is the primary substrate for energy production in the mitochondria, 
other substrates, such as alanine, glutamine [85,106,107], or branched chain amino acids [108], 
might bypass the MPC1/2 complex and enter into the mitochondrial matrix to compensate for the 
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lack of pyruvate transport under conditions where MPC1 or MPC2 is not present or functional. A 
clear limitation of our adipogenesis studies is that they are solely in vitro observations. Although 
our findings show that the loss of MPC expression in vitro has no effect on adipocyte development, 
other in vivo studies have found that C57BL/6 mice with an adipocyte-specific loss of MPC1 had 
increased fatty acid oxidation, increased levels of triglycerides in circulation, deficiencies in 
storage of TGs, and mitochondrial damage. It was also observed that heterozygous MPC1 
knockdown mice had decreased body weight, activity, fat accumulation, and low body shell 
temperatures during cold exposure [90,109]. 
An analysis of several mouse tissue samples revealed that MPCs are highly expressed in 
BAT, heart, lung, and skeletal muscle (Figure 2.4). This is an expected finding, as each of these 
are mitochondria-rich tissues. However, it has not been reported that MPC1 and MPC2 are more 
highly enriched in BAT than other mitochondria-rich tissues (Figure 2.4). Because MPCs are 
highly enriched in BAT depots, but not in WAT depots, we assessed whether MPCs were regulated 
in AT depots during diet-induced obesity (DIO). Although MPC1 was downregulated in BAT and 
WAT during high-fat feeding at the mRNA level (Figure 2.5), MPC1 protein expression was 
barely detectable and not obviously changed in the WAT of either male or female mice during 
high-fat feeding (data not shown). The differences in gene and protein expression could be due to 
a variety of factors including translational rates, protein degradation rates, or a combination of both 
factors [110]. However, it is a novel finding that MPC gene and protein expressions are 
downregulated in BAT of male, but not female, mice during DIO (Figures 2.5 and 2.6). It has been 
reported that reductions in diet-induced thermogenesis contribute to weight gain after consumption 
of high fat meals [111]. In addition, glucose oxidation rates are significantly decreased in subjects 
after consuming high-fat meals [111]. This literature suggests that the decreased MPC expression 
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correlates with decreased diet-induced thermogenesis that occurs with prolonged high-fat feeding. 
Also, the sex-specific regulation of MPCs (Figure 2.6) is likely attributed to sex-specific metabolic 
responses to high fat feeding in C57BL/6J mice [103]. Unlike male mice, previous studies have 
shown that female mice are more metabolically healthy, have reduced inflammation, and are more 
insulin sensitive despite having obesity while on HFD [102–104]. Accordingly, in our study the 
female mice on HFD had 27% higher adiposity than the male HFD-fed mice, but improved glucose 
metabolism during an intraperitoneal glucose tolerance test. Data in Figure 2.7 demonstrate that 
decreased MPC protein levels correlate with increased adiposity and glucose intolerance in male, 
but not female, mice. We speculate that the variations in expression of MPC1 and MPC2 between 
male and female mice are due to differences in metabolic health and that MPCs are specifically 
regulated in brown, but not white, AT depots in conditions of metabolic dysfunction.  
In summary, our findings demonstrate that (1) the expression of MPCs is induced during 
adipocyte development, but not required for adipogenesis, (2) a loss of MPC expression or activity 
during adipogenesis likely promotes the activation of alternative mechanisms to compensate for 
the loss of pyruvate transport, and (3) MPC expression is highly enriched in BAT but decreased 
as a result of high-fat feeding or diet-induced obesity. Future studies will be needed to determine 
which substrates can be utilized to compensate for the loss or dysfunction of MPCs. In addition, it 
is necessary to determine whether adipogenesis in BAT is dependent on MPCs. Also, future studies 
will be necessary to determine whether the observed in vitro effects on adipogenesis are similar to 
in vivo models.  
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CHAPTER 3. KAT8, LYSINE ACETYLTRANSFERASE 8, IS REQUIRED 




Histone acetyltransferases (HATs) are enzymes that transfer acetyl groups from acetyl CoA 
to specific lysine residues on target proteins that are often histones. Histone acetylation modulates 
chromatin structure and gene expression and is primarily controlled by HATs and reversed by 
histone deacetylases (HDACs). HATs acetylate other proteins besides histones and are now more 
commonly referred to as lysine acetyltransferases, or KATs. Of the family of KATs, KAT8 has 
been reported to play a role in many cellular functions. KAT8 was initially described as males-
absent-on-the-first (MOF) in Drosophila melanogaster, because it is a male-specific protein that 
exhibits lethality when mutated in males [62]. In Drosophila, KAT8 contributes to two regulatory 
complexes, male-specific lethal (MSL) and non-specific lethal (NSL), that both contribute to 
transcriptional activation [63] [64]. KAT8 is present in mammalian species in which the MSL 
complex is conserved [63]. KAT8, also known as MYST1, is a member of the MYST (MOZ, 
YBF2/SAS2, and TIP 60 protein 1) family of histone acetyltransferases that are characterized by 
their roles in post-translational modifications of histone and chromatin remodeling in eukaryotes 
[65] [66]. KAT8 and other MYST proteins have a conserved MYST domain that consists of an 
acetyl CoA-binding motif, as well as a CCHC-type zinc finger that confers substrate recognition 
[66]. KAT8 also has a N-terminal chromodomain (CHD) which plays a role in RNA binding 
[67,68], a HAT domain, and a chromobarrel domain (CBD) at the C-terminal which modulates 
HAT activity [62,63]. KAT8 has a variety of substrates and can modulate many biological 
processes, including cell cycle regulation, embryonic development and tumorigenesis [69–76,79].  
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The most thoroughly characterized target of KAT8 in mammalian cells is Histone 4 Lysine 
16 (H4K16), where it participates in protein complexes that are involved in transcriptional 
regulation [69]. KAT8 can also acetylate H4K5 and H4K8 [69]. Disruption of KAT8 expression 
and/or function can result in irregularities in cell cycle, cell proliferation, gene transcription, DNA 
damage repair, and early embryonic development, or promotion of tumorigenesis in a variety of 
cell types [69,70,79]. Histones are well-known targets for KAT8 activity, but KAT8 acetylates 
other proteins.  Acetylation of LSD1 (lysine-specific histone demethylase 1) by KAT8 is 
associated with reduced tumorigenesis [71], while KAT8-mediated acetylation of the tumor 
suppressor p53 promotes cellular apoptosis in response to DNA damage [72–74]. KAT8 can also 
acetylate DBC1 (deleted in breast cancer 1) and reduce its binding affinity for the histone 
deacetylase, sirtuin 1 (SIRT1) to increase SIRT1 activity [75].   
The incidence of obesity and related metabolic diseases, such as Type 2 Diabetes Mellitus, 
continues to rise around the world and represents one of the greatest public health challenges of 
our time. Obesity is characterized by the expansion of adipose tissue via hyperplasia and 
hypertrophy of adipocytes. Adipose tissue plays a key role in metabolic health, and disruption of 
adipocyte development or fat cell functions is associated with poor metabolic outcomes [112–114]. 
In addition to the roles of KAT8 described above, there is evidence that KAT8 can be influenced 
by or interact with proteins important in adipocyte development and function. It was reported that 
KAT8 expression is modulated by signal transducer and activator of transcription 5B (STAT5B) 
during adipogenesis [83]. Also, in HEK293T cells KAT8 has been shown to acetylate fatty acid 
synthase (FASN) and promote its degradation via ubiquitylation [76]. FASN is the principal 
enzyme of de novo lipogenesis and is critical for adipocyte development and function. Most 
importantly, a genome-wide associated study (GWAS) meta-analysis identified KAT8 as 1 of 97 
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body mass index (BMI)-associated loci that account for variations in BMI [84]. These studies 
prompted us to examine the role of KAT8 in adipogenesis.  
Our novel studies reveal that KAT8 is expressed in adipocytes and plays a role in adipocyte 
development in vitro. The use of small interfering RNA (siRNA) to knock down KAT8 expression 
in preadipocytes and adipocytes revealed that KAT8 expression is required for the adipogenesis 
of 3T3-L1 cells but does not affect lipid accumulation or adipocyte marker levels in mature 
adipocytes. In contrast with what has been observed in other cell types [76], loss of KAT8 
expression in adipocytes did not affect FASN levels.   
3.2 Materials and Methods 
Cell culture: Murine 3T3-L1 preadipocytes were grown in Dulbecco’s Modified Eagle’s Media 
(DMEM) (Sigma-Aldrich, St. Louis, MO) with 10% bovine calf serum. Two days after confluence, 
preadipocytes were induced to differentiate using a standard protocol and induction cocktail 
composed of 3-isobutyl-methylxanthine, dexamethasone, insulin (MDI), and 10% characterized 
fetal bovine serum (FBS) in DMEM. HyClone calf and fetal bovine sera were purchased from 
Thermo Scientific (Waltham, MA) or GE Healthcare Life Sciences (Marlborough, MA). The 
medium was changed every 48 -72 hours during growth and differentiation.  
Whole-cell extract preparation: Cell monolayers were rinsed once with phosphate-buffered 
saline (PBS) and then scraped into non-denaturing immunoprecipitation (IP) buffer containing 
10mM Tris (pH 7.4), 150mM NaCl, 1mM EGTA, 1mM EDTA, 1% Triton X-100, 0.5% IGEPAL 
CA-630, protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 μM pepstatin, 50 trypsin 
inhibitory milliunits of aprotinin, 10 μM leupeptin, 1 mM 1,10-phenanthroline), and phosphatase 
inhibitors (0.2mM sodium vanadate and 100 μM sodium fluoride). The whole-cell extracts were 
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stored at -80°C before being thawed and passed through a 20-gauge needle seven times, then 
clarified via centrifugation at 13,000 x g for 10 min at 4°C. 
Small interfering RNA (siRNA)-mediated knockdown during differentiation:  3T3-L1 
preadipocytes, approximately 70% confluent in 10-cm plates, were trypsinized and re-plated in 6-
well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free 10% bovine calf serum/DMEM. 
Using the protocol from Dharmacon, preadipocytes were transfected with 33 nM siRNA 
(Dharmacon, Lafayette, CO; Non-targeting siRNA Cat #: D-001810-10-50, siRNA targeting 
KAT8 Cat #: L-048962-01-0010) and the DharmaFECT Duo transfection reagent (Dharmacon, 
Lafayette, CO, Cat #: T-2010-03) in OptiMEM reduced serum medium (Thermo Fisher, Waltham, 
MA; Cat #: 31985088). Non-targeting siRNA was used as negative control. Cells were treated 
with the siRNA cocktail during initial plating and grown to confluence. Two days after confluence, 
cells were induced to differentiate with the MDI-induction cocktail, as described above, and 
transfected again with the siRNA cocktail. After 48 hours, the cells were treated with ¼ normal 
dose of insulin and transfected once again with the siRNA cocktail.  Cells were fed every 48 hours 
with antibiotic-free media throughout the entire knockdown process. Seven days after the 
induction of differentiation, the cell monolayers were harvested for protein in IP buffer, and for 
RNA in buffer provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown 
efficiency. Three biological and technical replicates were analyzed for each data set. 
Small interfering RNA (siRNA)-mediated knockdown in mature adipocytes: Fully 
differentiated 3T3-L1 adipocytes were trypsinized and re-plated in 6-well plates at a density of 5.8 
x 105 cells/cm2 in antibiotic-free 10% fetal bovine serum/DMEM. Using the protocol from 
Dharmacon, preadipocytes were transfected with 50 nM siRNA (Dharmacon, Lafayette, CO; Non-
targeting siRNA Cat #: D-001810-10-50, siRNA targeting KAT8 Cat #: L-048962-01-0010) and 
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the DharmaFECT Duo transfection reagent (Dharmacon, Lafayette, CO, Cat #: T-2010-03) in 
OptiMEM reduced serum medium (Thermo Fisher, Waltham, MA; Cat #: 31985088). Non-
targeting siRNA was used as negative control. Cells were treated with the siRNA cocktail during 
initial plating. The cell monolayers were harvested 48 hours later for protein in IP buffer, and for 
RNA in buffer provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown 
efficiency. Three biological and technical replicates were analyzed for each data set. 
Gel electrophoresis and immunoblotting:  Protein content of cell extracts was quantified via 
BCA assay. Samples were separated on 7.5%, 12%, or 15% sodium dodecyl sulfate (SDS) 
polyacrylamide (PA) gels (acrylamide; National Diagnostics, Atlanta, GA; Cat #: EC-890) and 
transferred to nitrocellulose membranes (BioRad, Hercules, CA; Cat #: 162-0115) in 25 mM Tris, 
192 mM glycine, and 20% methanol. After the transfer, membrane strips were blocked in 4% non-
fat milk for 1 hour at room temperature and washed with tris-buffered saline + 0.1% Tween-20 
(TBS-T) before incubating with primary antibodies in 1% BSA-TBS-T overnight at 4°C. Strips 
were washed with TBS-T and then incubated with either anti-mouse or anti-rabbit horseradish 
peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) for 1h. 
Strips were washed with TBS-T and visualized with enhanced chemiluminescence (Pierce/Thermo 
Scientific, Waltham, MA).  
Antibodies: Transferrin (ab82411; rabbit polyclonal) and the MitoProfile Total OXPHOS Rodent 
WB antibody mixture (ab110413; rabbit polyclonal) antibodies were purchased from Abcam 
(Cambridge, MA). Anti-PPARg (E-8; sc-7273; mouse monoclonal) antibody was purchased from 
Santa Cruz Biotechnology (Dallas, TX). Anti-adiponectin (PA1-054; rabbit polyclonal) antibody 
was purchased from Thermo Scientific (Waltham, MA). Anti-DBC1 (5693S; rabbit polyclonal), 
anti-FASN (3180S; C20G5; rabbit monoclonal), anti-ERK1/2 (4695S; 137F5; rabbit monoclonal), 
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and anti-MYST1 (4682S; D5T3R; rabbit monoclonal) antibodies were purchased from Cell 
Signaling Technology (Danvers, MA).  
RNA analysis: Total RNA from adipocyte monolayers was purified using the RNeasy mini kit 
(Qiagen, Hilden, Germany). Purified RNA was used for reverse transcription (RT) to generate 
cDNA according to the Applied Biosystems protocol (Applied Biosystems, Foster City, CA; Cat 
#: 4368813). cDNA was quantified using the real-time quantitative PCR (qPCR) method in a total 
volume of 10 µL (2 µL cDNA and 8 µL reaction master mix) using an Applied Biosystems 
7900HT System with SDS 2.4 software, Takara SYBR premix (Takara Bio USA Inc., Madison, 
WI, USA), and primers from IDT (Integrated DNA Technologies, Skokie, IL, USA). Thermal 
cycling conditions were as follows 2 min at 50 °C; 10 min at 95 °C; 40 cycles of 15 s at 95 °C and 
1 min at 600C; final dissociation stage of 15 s at 95 °C, 15 s at 60 °C, and 15 s at 95 °C. Non-POU 
domain containing octamer binding protein (NoNo) was used as a reference gene. The following 
mouse genes were examined by RT-qPCR: Adiponectin (Adpn), Fatty Acid Binding Protein 4 
(aP2), Fatty Acid Synthase (Fasn), Glucose Transporter 4 (Glut4), and Lysine Acetyltransferase 
8 (KAT8). Primer sequences are shown in Table 1.  
Lipid Staining: Seven days after the induction of differentiation, cells were fixed and stained with 
Oil Red O (ORO; Sigma-Aldrich, St. Louis, MO, USA) as described previously [19].  
Statistical analysis: Statistical analyses were performed using GraphPad Prism software (version 
8; La Jolla, CA, USA). Differences between groups were calculated using two-way ANOVA. 
Results are shown as mean ± standard error of the mean (SEM). Results were considered 
statistically significant when p < 0.05.  
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Table 3.1. qPCR Primer Sequences  






























We examined the expression of KAT8 mRNA and protein over a time course of adipocyte 
development using the 3T3-L1 model system. As shown in Figure 3.1A, KAT8 protein levels were 
highest in preadipocytes (time 0) but did not change over the period of adipocyte development. As 
expected, adiponectin levels increased during adipogenesis, and ERK levels were unchanged. 
Similarly, there we no effects on Kat8 gene expression during adipogenesis despite the time-
dependent increase in aP2, adiponectin, and fatty acid synthase mRNA levels (Figure 3.1B).  In 
mature adipocytes, subcellular fractionation demonstrated that although KAT8 primarily localizes 
in the nucleus, it is also present in the cytosol, but not in the mitochondria (Figure 3.2).  DBC1 
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was utilized as a positive control for nuclear protein and ERK1/2 was utilized as a positive control 
for cytosolic protein. COX1 was used as positive control for mitochondrial protein.  
To assess the requirement of KAT8 for adipogenesis, we performed siRNA-mediated 
knockdowns of KAT8 in 3T3-L1 preadipocytes prior to adipogenesis and assessed adipocyte 
differentiation 7 days post-induction. Effective knockdown of the Kat8 gene was confirmed by 
qPCR (Figure 3.3A). The induction of three adipogenic mRNAs, adiponectin (Adpn), aP2/FABP4, 
and fatty acid synthase were also inhibited with KAT8 knockdown. The loss of KAT8 protein was 
confirmed by western blot analysis and was associated with reduced expression of adiponectin and 
PPARg, the primary regulator of adipogenesis (Figure 3.3B). ERK levels were examined as a 
loading control. Loss of KAT8 during adipogenesis was also associated with an inhibition of lipid 
accumulation as judged by Oil Red O staining of neutral lipids (Figure 3.3C). Although FASN 
mRNA expression is markedly decreased, non-targeting siRNA did not attenuate adipocyte marker 
protein expression or lipid accumulations (Figures 3.3A-C). 
We also performed siRNA-mediated knockdowns of KAT8 in mature adipocytes to 
evaluate potential effects on lipid accumulation and expression of adipogenic markers. Unlike the 
loss of KAT8 during differentiation of preadipocytes, a significant loss of Kat8 expression in 
mature 3T3-L1 adipocytes was not associated with decreased expression of various adipogenic 
marker mRNAs, including adiponectin, aP2, Glut4, and Fasn (Figure 3.4A). Although KAT8 
protein expression was significantly reduced, there were no differences in protein expression of 
adiponectin or FASN in the KAT8 siRNA-transfected condition as compared to non-targeting 
siRNA in adipocytes (Figure 3.4B). Of note, the siRNA treatments were associated with decreased 
expression of adiponectin and FASN and with an increase in transferrin levels, but these effects 
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were not due to the loss of KAT8. In addition, loss of KAT8 in mature adipocytes had no effect 
on neutral lipid accumulation, as judged by Oil-Red O staining (Figure 3.4C).  
 
Figure 3.1. KAT8 expression over a time course adipogenesis in 3T3-L1 cells. 3T3‐L1 
preadipocytes were induced to differentiate using the 3‐isobutyl‐methylxanthine, dexamethasone, 
insulin (MDI) cocktail, and cells were harvested at the indicated time points to assess KAT8 gene 
and protein expression over a time course of adipocyte differentiation. (A) Whole‐cell extracts (50 
µg of protein per lane) were subjected to Western blot analysis. Adiponectin was utilized as a 
positive control for adipogenesis. (B) RNA was isolated, purified, and subjected to RT‐qPCR to 
measure gene expression of Kat8, adipogenic markers (adiponectin [Adpn], fatty acid synthase 
[Fasn], and fatty acid binding protein [aP2] (n = 3 wells per treatment). Marker gene expression 





Figure 3.2. KAT8 is expressed in the nucleus and cytosol of 3T3-L1 cells, but not in mitochondria. 
Monolayers of fully differentiated 3T3-L1 cells were collected and subjected to subcellular 
fractionation that was optimized to separate cytosolic (cyto), nuclear (nuc), and mitochondrial 
(mito) fractions. Fractionated samples (40 µg of protein per lane) were subjected to Western blot 
analysis. This experiment was independently performed on three different batches of adipocytes 




Figure 3.3. KAT8 expression is required for adipogenesis of 3T3‐L1 cells. 3T3‐L1 preadipocytes 
were transfected with non-targeting (NT) siRNA or KAT8 siRNA upon plating and every 48 hours 
following induction of differentiation with MDI cocktail until end point assessments. Protein and 
gene expression assessments as well as Oil Red O staining were conducted on the cells at 7 days 
post MDI. (A) RNA was isolated, purified, and subjected to RT‐qPCR to assess gene expression 
of Kat8 and adipogenic markers (adiponectin [Adpn], fatty acid synthase [Fasn], and fatty acid 
binding protein 4 [aP2]). Data were analyzed by two‐way ANOVA. *P < 0.05 and ****P < 0.0001 
vs. NT control (n= 3 wells per treatment). (B) Whole‐cell extracts were isolated, and 40 µg 
of protein per lane was analyzed by Western blot analysis (n= 2-3 pooled 
replicates/well/treatment). (C) Cells were fixed and stained with Oil Red O to examine lipid 
accumulation. Each panel is representative of an experiment performed on at least three 
independent batches of cells.  
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Figure 3.4. The loss of Kat8 in mature 3T3‐L1 adipocytes does not affect adipocyte marker 
expression or neutral lipid content. Fully differentiated 3T3‐L1 adipocytes were transfected with 
non-targeting (NT) siRNA or KAT8 siRNA. Cells were harvested for protein and gene expression 
assessments or fixed for Oil Red O staining 48 hours post-transfection. (A) RNA was isolated, 
purified, and subjected to RT‐qPCR to examine gene expression of Kat8 and adipogenic markers 
(adiponectin [Adpn], fatty acid binding protein 4 [aP2], glucose transporter 4 [Glut4], and fatty 
acid synthase [Fasn]). Data were analyzed by two‐way ANOVA. *P < 0.05 and ****P < 0.0001 
vs. NT control (n= 3 wells per treatment). (B) Whole‐cell extracts and media were isolated and 
150 µg of protein per lane was analyzed by Western blot analysis (n= 3 replicates/treatment). (C) 
Cells were fixed and stained with Oil Red O to examine neutral lipid accumulation. Each panel is 
representative of at least three experiments performed on independent batches of adipocytes.  
 
3.4 Discussion 
KAT8 is expressed in preadipocyte and adipocytes, but neither KAT8 mRNA nor protein 
levels are highly regulated during adipogenesis (Figure 3.1). Another study has indicated that 
KAT8 expression is increased during adipocyte differentiation in the 3T3-L1 model system. [83]. 
However, our gene and protein expression data from experiments repeated several times do not 
support this observation. Of note, KAT8 expression is regulated during differentiation of other cell 
 45 
types, including oocytes and glioblastomas [115,116]. In addition, KAT8 has also been shown to 
be required in the maintenance of embryonic stem cell self-renewal and pluripotency [117], and 
siRNA-mediated loss of KAT8 impairs formation and proliferation of porcine blastocysts [118]. 
In vitro, adipogenesis is dependent on a process referred to as mitotic clonal expansion, where 
cells undergo one to two rounds of proliferation prior to differentiation and a permanent exit from 
the cell cycle. It is possible that KAT8 is required for adipogenesis in vitro, due to its effects on 
regulating proliferation. Future studies will be needed to determine if KAT8 is a crucial modulator 
of adipogenesis in vivo. 
In adipocytes, we observed that KAT8 is present in the cytosol, but KAT8 protein levels 
are enriched in the adipocyte nucleus (Figure 3.2). KAT8 subcellular localization varies between 
cell types. In HeLa cells, KAT8 is found in the mitochondria where it binds mitochondrial DNA 
and regulates mitochondrial gene expression associated with respiration [119]. Notably, in HeLa 
cells lacking KAT8, a mitochondrial wild-type KAT8, but not a catalytic mutant, can restore 
respiratory and transcriptional defects induced by loss of KAT8 [119]. Further support for a role 
of KAT8 in mitochondrial respiration comes from studies in failing human and murine hearts, 
where KAT8 expression is decreased [120]. Future studies will be needed to determine how the 
nuclear and mitochondrial pools of KAT8 contribute to regulation of transcription and energy 
metabolism in complex tissues, including adipose tissue.  
Use of siRNA knockdowns revealed that KAT8 expression is required for adipogenesis in 
the 3T3-L1 model system (Figure 3.3). The only other study of KAT8 in adipocytes indicated that 
KAT8 was increased during adipogenesis, and that the KAT8 promoter was bound by STAT5B 
[83]. In that study, loss of KAT8 led to increased expression of adipocyte marker genes and the 
 46 
study’s authors concluded that KAT8 and STAT5B were negative regulators of adipogenesis. 
However, STAT5 proteins are well-known positive regulators of adipocyte development in vitro 
and in vivo [121,122]. Hence, these observations are in conflict with the data from our rigorous 
studies and with what is known about STAT5’s role in adipogenesis.  To our knowledge, there are 
no published studies on loss of KAT8 in adipocytes in vitro or in vivo. Our data reveal that loss of 
KAT8 in mature adipocytes is not accompanied by decreased expression of adipocyte markers 
such as adiponectin, fatty acid synthase, or GLUT4 (Figure 3.4A and B). Moreover, a 48-hour 
knockdown of KAT8 produced no changes in neutral lipid accumulation in adipocytes (Figure 
3.4C). These data suggest that KAT8 has different functions in preadipocytes and adipocytes, 
which is not a surprise given the diverse functions of KAT8 in a variety of cell types.  
Since KAT8 has cell-specific functions, it will be important to determine the function of 
this acetyltransferase during adipogenesis as well as in mature adipocytes. Our observations on 
KAT8 are novel and, except for the study cited above, there are no other data on KAT8 in 
adipocytes. However, a GWAS study has identified KAT8 in a locus associated with variability in 
body mass index [84]. Of other possible relevance is a study in HEK293 cells showing that KAT8 
can regulate fatty acid synthase (FASN) expression via acetylation [76]. Since FASN is essential 
for lipogenesis, we predicted that FASN might be a substrate of KAT8 in mature adipocytes. 
However, loss of KAT8 in mature fat cells did not affect FASN expression (Figure 3.4B) or half-
life (data not shown). Overall, our data demonstrate that KAT8 is required for in vitro 
adipogenesis, but not for expression of adipocyte markers in mature fat cells. These data suggest 
that KAT8 likely has different functions in preadipocytes and adipocytes. In adipocytes, KAT8 is 
largely present in the nucleus, suggesting it is likely involved in transcriptional regulation. Our 
current efforts are focused on identifying KAT8 substrates in mature adipocytes. Given its role in 
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adipogenesis and its expression in adipocyte nuclei, it is likely that KAT8 contributes to fat cell 






CHAPTER 4. KAT8, LYSINE ACETYLTRANSFERASE 8, IS EXPRESSED 
AND NUTRITIONALLY REGULATED IN ADIPOSE TISSUE 
4.1 Introduction 
Although many epigenetic modifiers have been characterized, much remains unknown 
about their roles in vivo. KATs are a group of epigenetic modifiers characterized by their ability 
to reversibly acetylate histones and many other proteins. Approximately 15 KATs have been 
identified and categorized into 3 families: the MYST family (for Moz, Ybf2/Sas3, Sas2, and 
Tip60),  the general control nonderepressible 5 (GCN5) family, and the CREB-binding protein 
(CBP) family [123–125]. Within the MYST family there are 5 KATs (KAT5, KAT6A, KAT6B, 
KAT7, and KAT8) that have been characterized and show target specific acetylation of histones. 
KAT6A and KAT6B acetylate histone 3 lysine 23 (H3K23) while KAT7 acetylates at H3K14 
[125]. Unlike other members of the MYST family, KAT8 acetylates histone 4 at lysine 16 (H4K16) 
suggesting differing functionality than other MYST members [125]. 
As previously stated, the exponential increase in the global incidence of obesity and 
metabolic diseases has serious health-related and economic repercussions around the world. 
Adipose tissue is known to play a critical role in metabolic health and is the subject of intense 
study as a potential therapeutic target for metabolic dysfunction.  KAT8 plays a role in cell cycle 
progression, cell proliferation, DNA damage repair, gene transcription, promotion of autophagy, 
tumorigenesis, and early embryonic development [69,70,77–79]. However, there is only scant 
evidence for a role of KAT8 in adipocytes, and no mechanistic studies have assessed KAT8 in 
adipose tissue.  
In order to further evaluate the potential functions of KAT8 in fat, we examined KAT8’s 
expression and regulation in adipose tissue. Our novel studies reveal that KAT8 is highly expressed 
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in various white adipose tissue (WAT) depots. In addition, tissue digestion and fractionation 
reveals that KAT8 expression is enriched in adipocytes, but also expressed in non-adipocyte cells 
of adipose tissue. We have also demonstrated that KAT8 is nutritionally regulated by DIO and 
fasting/refeeding. Although the mechanisms are unknown, these findings advance the field and 
lead to a deeper understanding of KAT8 functionality in adipose tissue.   
4.2 Materials and Methods 
Animals and Diets- Four-week-old male and female C57BL/6J mice were purchased from 
Jackson Laboratories (Stock #000664; Bar Harbor, ME). Animals were housed in a temperature 
(22 ± 2°C)- and humidity-controlled (45–55%) room under a 12-h light/dark cycle. At six weeks 
of age, mice were placed on respective diets with ad libitum access to food and water. For twelve 
weeks, mice had access to either low-fat diet (LFD) containing 20% kcal protein, 70% kcal 
carbohydrate, and 10% kcal fat (D12450J; Research Diets, Inc. New Brunswick, NJ) or high-fat 
diet (HFD) containing 20% kcal protein, 20% kcal carbohydrate, and 60% kcal fat (D12492; 
Research Diets, Inc. New Brunswick, NJ). Body weights were obtained biweekly. Mice were 
fasted for four hours prior to sacrifice. For fasting and refeeding studies, thirteen-week-old female 
mice were either fasted for eighteen hours or fasted for fourteen hours then allowed ad 
libitum access to food and water for four hours before sacrifice. All animal studies were performed 
with approval from the Pennington Biomedical Research Center Institutional Animal Care and 
Use Committee. 
Cell culture- Murine 3T3-L1 preadipocytes were grown in Dulbecco’s Modified Eagle’s Media 
(DMEM) (Sigma-Aldrich, St. Louis, MO) with 10% bovine calf serum. Two days after confluence, 
the preadipocytes were induced to differentiate using a standard protocol and induction cocktail 
composed of 3-isobutyl-methylxanthine, dexamethasone, insulin (MDI), and 10% characterized 
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fetal bovine serum (FBS) in DMEM. HyClone calf and fetal bovine serum were purchased from 
Thermo Scientific (Waltham, MA) or GE Healthcare Life Sciences (Marlborough, MA). The 
medium was changed every 48 – 72 hours during growth and differentiation. Cells were treated 
with 5 µM cycloheximide (CHX) for indicated times before harvesting cell monolayers. 
Whole-cell extract preparation- Cell monolayers were rinsed once with phosphate-buffered 
saline (PBS) and then scraped into non-denaturing immunoprecipitation (IP) buffer. These extracts 
were stored at -80°C before being thawed, passed through a 20-gauge needle five times, and 
clarified via centrifugation at 13,000 x g for 10 min at 4°C. 
Small interfering RNA (siRNA)-mediated knockdown during differentiation:  3T3-L1 
preadipocytes, approximately 70% confluent in 10-cm plates, were trypsinized and re-plated in 6-
well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free 10% bovine calf serum/DMEM. 
Using the protocol from Dharmacon, preadipocytes were transfected with 33 nM siRNA 
(Dharmacon, Lafayette, CO; Non-targeting siRNA Cat #: D-001810-10-50, siRNA targeting 
KAT8 Cat #: L-048962-01-0010) and the DharmaFECT Duo transfection reagent (Dharmacon, 
Lafayette, CO, Cat #: T-2010-03) in OptiMEM reduced-serum medium (Thermo Fisher, Waltham, 
MA; Cat #: 31985088). Non-targeting siRNA was used as negative control. Cells were treated 
with the siRNA cocktail during initial plating and grown to confluence. Two days after confluence, 
cells were induced to differentiate with the MDI-induction cocktail, as described above, and 
transfected again with the siRNA cocktail. After 48 hours, the cells were treated with ¼ normal 
dose of insulin and transfected once again with the siRNA cocktail.  Cells were fed every 48 hours 
with antibiotic-free media throughout the entire knockdown process. Seven days after the 
induction of differentiation, the cell monolayers were harvested for protein in IP buffer, and for 
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RNA in buffer provided in the RNeasy mini kit (Qiagen, Hilden, Germany) to assess knockdown 
efficiency. 
Gel electrophoresis and immunoblotting- Protein content of cell extracts was quantified via 
BCA assay. Samples were separated on 7.5%, 12%, or 15% sodium dodecyl sulfate (SDS) 
polyacrylamide (PA) gels (acrylamide; National Diagnostics, Atlanta, GA; Cat #: EC-890) and 
transferred to nitrocellulose membranes (BioRad, Hercules, CA; Cat #: 162-0115) in 25 mM Tris, 
192 mM glycine, and 20% methanol. After the transfer, membrane strips were blocked in 4% non-
fat milk for 1 hour at room temperature and washed with tris –buffered saline + 0.5% Tween-20 
(TBS-T) before incubating with primary antibodies overnight at 4°C. Strips were washed with 
TBS-T and then incubated with either anti-mouse or anti-rabbit horseradish peroxidase-conjugated 
secondary antibodies (Jackson ImmunoResearch, West Grove, PA) for 1h. Strips were washed 
with TBS-T and visualized with enhanced chemiluminescence (Pierce/Thermo Scientific, 
Waltham, MA).  
Antibodies- Anti-STAT5A (L-20; sc-1081; rabbit polyclonal), anti-adipsin (M-120; sc-50419; 
rabbit polyclonal), anti-STAT3 (C-20; sc-482; rabbit polyclonal), anti-PPARg (E-8; sc-7273; 
mouse monoclonal), anti-PDK4 (C-16; sc-14495; goat polyclonal), and anti-ERK1/2 (C-16; sc-
93; rabbit polyclonal) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX). 
Anti-adiponectin (PA1-054; rabbit polyclonal) antibody was purchased from Thermo Scientific 
(Waltham, MA). Anti-FASN (3180S; C20G5; rabbit monoclonal), anti-ERK1/2 (4695S; 137F5; 
rabbit monoclonal), anti-ß-actin (3700; 8H10D10; mouse monoclonal), anti-ATGL (2439; 30A4; 
rabbit monoclonal), and anti-MYST1 (4682S; D5T3R; rabbit monoclonal) antibodies were 
purchased from Cell Signaling Technology (Danvers, MA). Anti-GAPDH (ab9485; rabbit 
polyclonal) antibody was purchased from Abcam (Cambridge, MA). 
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RNA analysis- Total RNA from tissue samples was extracted according to TRIzol manufacturer 
instructions. RNA from tissue or adipocyte monolayers was purified using the RNeasy mini kit 
(Qiagen, Hilden, Germany). Ten microliters of purified RNA were used for reverse transcription 
(RT) to generate cDNA according to the Applied Biosystems protocol (Applied Biosystems, Foster 
City, CA; Cat #: 4368813). cDNA was quantified using the real-time quantitative PCR (qPCR) 
method in a total volume of 10µL (2µL DNA and 8µL reaction master mix) using an Applied 
Biosystems 7900HT System with SDS 2.4 software. qPCR was performed using Takara SYBR 
premix (Takara Bio USA Inc., Madison, WI, USA) and primers from IDT (Integrated DNA 
Technologies, Skokie, IL, USA). Thermal cycling conditions were as follows  2 min at 500C ; 10 
min at 950C; 40 cycles of 15 s at 950C and 1 min at 600C; final dissociation stage of 15 s at 950C, 
15 s at 600C, and 15 s at 950C. Cyclophilin A (Ppia) and Non-POU domain containing octamer 
binding protein (NoNo) were used as reference genes. The following mouse genes were examined 
by RT-qPCR: Adiponectin (Adpn), Fatty Acid Binding Protein 4 (aP2), Adipsin (Cfd), Fatty Acid 
Synthase (Fasn), and Lysine Acetyltransferase 8 (Kat8). Primer sequences are shown in Table 1.  
Statistical analysis- Statistical analyses were performed using GraphPad Prism software (version 
8; La Jolla, CA, USA). Differences between groups were calculated using Student’s t-tests and 
two-way ANOVA. Results from studies of cultured adipocytes are shown as mean ± standard error 
of the mean (SEM). Results were considered statistically significant when p < 0.05.  
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Table 4.1. qPCR Primer Sequences 


























Adipsin (Cfd) CGAGGCCGGATTCTGGG GAGTCGTCATCCGTCACTCC 
Lysine 
Acetyltransferase 




4.3.1 KAT8 is highly expressed in white adipocytes in vivo 
 To examine the relative tissue distribution of KAT8 in C57BL/6J mice, we assessed its 
expression in many tissues, including several adipose tissue depots. As shown in Figure 4.1, KAT8 
is expressed in many tissues such as the lungs, heart, and spleen. More importantly, KAT8 is highly 
expressed in white adipose tissue (WAT) depots, such as inguinal WAT (iWAT), gonadal WAT 
(gWAT), retroperitoneal WAT (rpWAT), and mesenteric WAT (mWAT), but not brown adipose 
tissue (BAT). Among adipose tissue depots, KAT8 is most highly expressed in iWAT. This data 
suggests a potential role for KAT8 in adipose tissue.  
 In Drosophila melanogaster, KAT8 is referred to as a male-specific protein. To assess sex 
specificity of KAT8 in C57BL/6J mice, we compared expressions of KAT8 between sexes in the 
 54 
GI tract (Figure 4.2A), gonads, adipose tissue, and lungs (Figure 4.2B). While there was no male 
specificity in any of the tissues KAT8 expression in the small intestines, ovaries, iWAT, and 
rpWAT was elevated in female mice compared to males. Lungs, mWAT, and BAT/WAT had 
similar expressions of KAT8 in both male and female mice. These data show that KAT8 is not a 
male-specific protein in C57BL/6J mice. 
 Because KAT8 is highly expressed in adipose tissue, it was essential to determine whether 
KAT8 was expressed in the adipocytes or stromavascular fractions (SVF) of iWAT and eWAT of 
male and female C57BL/6J mice. Adipose tissues were digested and fractionated to isolate 
adipocytes and SVF to assess KAT8 expression. Figure 4.3 shows that KAT8 is expressed in both 
adipocytes and SVF, but KAT8 is more highly expressed in adipocyte fractions of both male and 
female mice. This data also shows that KAT8 expression is more robust in the adipocytes of female 
mice versus males. The SVF of iWAT and eWAT contains multiple other cell types and further 
studies would be required to determine which cell types express KAT8 within the SVF. Moreover, 
this data shows that KAT8 is more localized within the adipocytes. Together, these data strongly 
suggest a role for KAT8 in white adipocytes. 
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Figure 4.1. KAT8 is highly expressed in white adipose tissue depots and lungs. Select tissues were 
harvested from a 27-week old C57BL/6J mouse. Tissue samples were homogenized, and protein 
was isolated. 100 µg of total protein per lane were analyzed by Western blotting. gWAT, gonadal 
WAT; rpWAT, retroperitoneal WAT; iWAT, inguinal WAT; mWAT, mesenteric WAT; BAT, 




Figure 4.2. KAT8 is highly expressed in WAT tissue depots of C57Bl/6J mice but does not exhibit 
male specificity. Tissue samples were subjected to homogenization and protein isolation. 100 µg 
of total protein per lane were analyzed by Western blotting. KAT8 expression was assessed in the 
adipose tissue depots, gonads, (A) GI tract, and (B) lungs of both male and female C57BL/6J mice. 
STAT5A was utilized as an adipose tissue marker. ERK 1/2 was utilized as a loading control. SI, 






Figure 4.3. KAT8 is highly expressed in adipocytes of C57BL/6J tissue fractions. Adipocytes and 
stromavascular fractions (SVF) were isolated via collagenase digestion in iWAT and eWAT 
depots of male and female C57Bl/6J mice. 50 µg of total protein per lane were analyzed by Western 
blotting. Adiponectin was utilized as an adipocyte marker and ERK ½ as a loading control. (n=2)  
 
4.3.2 KAT8 is nutritionally regulated by diet-induced obesity and fasting 
To determine whether KAT8 expression was regulated by diet-induced obesity (DIO), 
C57BL/6J mice were subjected to either low-fat (LF) or high-fat (HF) diets for 12 weeks. Inguinal 
WAT (iWAT), gonadal/epididymal WAT (g/eWAT), and BAT were harvested and analyzed in 
both male and female mice (Figure 4.4). In female mice, KAT8 expression was not regulated by 
DIO in either gWAT or iWAT at the protein level (Figures 4.4A and C, respectively). Figure 4.5B 
also exhibits no significant transcriptional regulation of Kat8 in female mice after prolonged high-
fat feeding despite the expected downregulation of fatty acid synthase (Fasn) and adipsin (Adpsn). 
In contrast, KAT8 protein expression is upregulated in eWAT and iWAT during prolonged high-
fat feeding in males (Figures 4.4B and D, respectively). Despite the upregulation of KAT8 at the 
protein level, Kat8 mRNA expression is not regulated during high-fat feeding in male mice (Figure 
4.5A). These data suggest that KAT8 protein expression is upregulated by DIO. 
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To further assess nutritional regulation of KAT8, we examined KAT8 expression in 
thirteen-week-old female C57BL/6J mice subjected to either eighteen hours of fasting (Fasted) or 
fourteen hours of fasting followed by four hours of ad libitum refeeding with chow (Refed). KAT8 
expression was assessed in iWAT, gWAT, rpWAT, BAT, and liver upon harvest. In Figure 4.6, 
we observed an upregulation of KAT8 protein expression with refeeding in each of the adipose 
tissue depots, but not in the liver of female mice. This upregulation of KAT8 was more pronounced 
in iWAT, gWAT, and rpWAT of female mice and more modest in BAT (Figures 4.6A-D). 
Although we did not see the expected upregulation of FASN during refeeding, we did observe the 
expected upregulation of PDK4 during fasting in the liver (Figure 4.6E). This study indicates that 
KAT8 is regulated by fasting and refeeding. Altogether, Figures 4.4-4.6 clearly show that KAT8 
is nutritionally regulated in vivo. 
4.3.3 KAT8 is a stable protein and does not affect FASN and PPARg turnover in vitro 
 Current literature suggests that KAT8 interacts with and acetylates FASN to promote 
protein degradation of FASN via ubiquitylation [76]. To determine KAT8 and FASN protein 
stability, 3T3-L1 cells were treated with cycloheximide (CHX) for indicated time points in the 
presence and absence of KAT8. Under basal conditions in the presence of CHX, KAT8 and FAS 
expression was unaffected despite the expected decline in PPARg protein expression indicating 
that both FASN and KAT8 are relatively stable proteins (Figure 4.7A). Next, a siRNA-mediated 
knockdown of KAT8 was performed and 3T3-L1 cells were subjected to CHX treatments. Figure 
4.7B shows that FASN expression is unaffected by the loss of KAT8 in 3T3-L1 cells, indicating 





Figure 4.4. KAT8 expression is significantly upregulated in the eWAT and iWAT of male, but not 
female mice following high-fat feeding. Six-week old male and female C57BL/6J mice were fed 
either a high-fat (HF) or low-fat (LF) diet for 12 weeks ad libitum before euthanizing and collecting 
adipose tissue. Tissue samples were homogenized, and 30 µg of total protein per lane were 
subjected to Western blot analysis (n = 6 per condition) for males (B, D) and females (A, C). 
Adipsin was utilized as a control for high fat feeding. STAT3 was utilized as a loading control. 
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Figure 4.5. Steady state mRNA expression of Kat8 is not significantly regulated in adipose tissue 
after high-fat feeding in male and female C57BL/6J mice. Six-week old C57BL/6J mice were fed 
either a high-fat (HF) or low-fat (LF) diet for 12 weeks ad libitum before euthanizing and collecting 
tissue. BAT, iWAT, and gWAT samples were homogenized and RNA was isolated and purified 
from each tissue depot for male (A) and female (B) mice. Each sample was subjected to RT-qPCR 
to show gene expression of Kat8, adipogenic markers (Adpn, Ap2, and Fas), and adipokine 
(Adipsin). Data was analyzed by unpaired t-tests. * indicates p < 0.05, ** indicates p < 0.01, *** 
indicates p < 0.001, and **** indicates p < 0.0001 vs.  LF diet (n = 6 per condition). Each sample 
was ran in duplicates. Target gene expression was normalized to the reference gene, Cyclophilin 





Figure 4.6. KAT8 expression is significantly increased in adipose tissue (WAT), but not in liver 
of female mice during refeeding. Thirteen-week old female C57BL/6J mice were fed chow diet 
and were fasted for either 18 hours, or for 14 hours and refed for 4 hours ad libitum before tissue 
collection. KAT8 expression was assessed in the (A) iWAT, (B) gWAT, (C) rpWAT, (D) BAT, 
and (E) liver during fasting and refeeding. 75 µg of total protein per lane were subjected to Western 




Figure 4.7. KAT8 does not affect FAS or PPAR! turnover in 3T3-L1 adipocytes. (A) Fully 
differentiated 3T3-L1 cells were treated with CHX and harvested at the indicated time points, and 
KAT8 expression was assessed. (B) Fully differentiated 3T3-L1 adipocytes were transfected with 
non-targeting siRNA (NT) or KAT8 siRNA for 48 hours prior to harvest and endpoint assessments 
were conducted on the cells. Whole-cell extracts were isolated and 50 µg protein per lane were 
analyzed by Western blot analysis (n=2 pooled samples/lane). ERK 1/2 was utilized as a loading 
control. 
4.4 Discussion 
Our novel data suggest that KAT8 has a role of importance in adipose tissue.  The analysis 
of many mouse tissue samples revealed that KAT8 is highly expressed in WAT and lungs. It is not 
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surprising that KAT8 is highly expressed in the lungs, as KAT8 has been studied as a target cancer 
therapeutic in lung cancer for its ability to suppress p53 activation and regulate G2/M cell cycle 
arrest [126]. However, the unexpected findings of the robust expression of KAT8 in WAT of 
C57BL/6J mice has not been reported to our knowledge (Figure 4.1). Although KAT8 is a male-
specific protein in Drosophila melanogaster [62], this is not the case in C57BL/6J mice (Figure 
4.2). Rather, enhanced expression of KAT8 in rpWAT and gonads of female mice could suggest 
differential roles of KAT8 in D. melanogaster and mus musculus. However, this requires further 
study.  
Similarly, robust expression of KAT8 in adipocyte fractions of WAT of male and female 
mice further suggests a role for KAT8 in adipocytes (Figure 4.3). Because KAT8 is highly enriched 
in WAT depots, we assessed whether KAT8 was regulated in AT during DIO. KAT8 is 
upregulated during DIO in male mice at the protein level (Figure 4.4), but not regulated at the 
mRNA level (Figure 4.5). These differences between mRNA and protein expression could result 
from differences in translational rates, protein degradation, or both [110]. As for sex-specific 
differences in KAT8 regulation, they could be due to differing metabolic responses to prolonged 
high-fat feeding in C57BL/6J mice [103]. Female C57BL/6J mice have been shown to be more 
metabolically healthy, insulin sensitive, and have reduced inflammation despite displaying the 
obese phenotype while on HFD [102–104].  
The regulation of KAT8 expression in AT by refeeding has not been reported by any other 
group (Figure 4.6). Currently, mechanisms by which these effects are mediated are unknown and 
require further study. Although we suspected that KAT8 might be mediating its effects via its 
interaction with FASN, this now appears unlikely, as CHX studies revealed that the loss of KAT8 
in mature adipocytes has no effect on FASN expression or turnover rates [76]. Nonetheless, these 
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data all strongly suggest the KAT8 has essential roles in the function and development of adipose 
tissue. Our findings demonstrate that (1) KAT8 is highly expressed in adipocytes and adipose 
tissue, (2) KAT8 is nutritionally regulated by diet-induced obesity and fasting/refeeding, and (3) 
KAT8 has no effect on protein turnover of FASN. Future studies will be needed to determine how 
KAT8 functions in adipocytes and how it modulates adipose tissue development. 
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CHAPTER 5. CONCLUDING REMARKS 
 
Our novel studies provide further understanding of adipocyte development and regulation 
of two uncharacterized adipocyte proteins.  The contribution of MPCs and KAT8 to adipocyte 
development and the regulation of these two proteins in mature adipocytes has not been 
extensively studied until now. Most studies of MPCs in adipocytes focus on the function of MPCs 
in brown adipocytes, rather than white adipocytes. On the contrary, KAT8 has been extensively 
studied for its role in histone modification and off-target substrate acetylation, but there is limited 
literature on KAT8 regulation or function in preadipocytes or adipocytes. Our studies explore the 
function and regulation of both MPCs and KAT8 in adipocytes and adipose tissue during metabolic 
dysfunction. 
Because MPC protein expression was upregulated during adipogenesis, we expected MPCs 
to be required for adipocyte development. MPCs were thought to be required for adipogenesis due 
to its requirement for pyruvate transport into the mitochondrial matrix. Surprisingly, in vitro 
studies clearly show that the loss in functionality of the MPC complex, via knockdowns and 
pharmacological inhibition, has no noticeable effects on adipogenesis in 3T3-L1 cells. Inhibition 
of pyruvate transport associated with MPCs did not alter lipid accumulation, adipocyte 
development, or expression of adipogenic genes. This suggests that there are other mechanisms 
that can compensate for the loss of functionality of the MPC complex, such as pyruvate-alanine 
cycling [106]. These findings could also suggest that in the event that MPC functionality is lost, 
there are alternative substrates that can bypass the MPC complex, such as alanine, glutamine, and 
branched chain amino acids [85,106–108]. The limitation of these studies is that they were only 
performed in vitro, and future studies should be performed in vivo. 
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On the other hand, the loss of KAT8 in vitro completely inhibited adipocyte development. 
One published study has suggested that KAT8 is a negative regulator of adipogenesis [83]. 
However, our data indicate that KAT8 is a positive regulator of adipogenesis. Our results used the 
same model system and were repeated several times so we are confident in our results. In addition, 
Gao et. al. reported findings that were contrary to published literature. Unlike MPCs, KAT8 
expression was not highly regulated during adipogenesis but was required for adipogenesis. Loss 
of KAT8 expression resulted in severely impaired lipid accumulation and adipocyte development 
in vitro. However, the mechanism by which KAT8 is mediating its effects is currently unknown. 
Since KAT8 plays a role in proliferation, this might be the reason that it is needed for in vitro 
adipogenesis, which is dependent on mitotic clonal expansion. If the role of KAT8 is limited to 
preadipocyte proliferation, it might play a role in adipogenesis in vivo. Because there are no 
mechanistic studies of KAT8 in adipocytes, it is challenging to perform studies to identify its 
function(s) in mature fat cells. Nonetheless, it is clear that KAT8 plays an essential role in 
adipocyte development and likely impacts adipocyte function in vitro. Future studies will be 
required to determine the functional relevance of KAT8 in adipocyte in vitro and in vivo. 
In vivo, our novel data demonstrate that MPC1 and MPC2 expression are enriched in 
tissues such as BAT, liver, heart, lungs, and kidney. This was expected because each of these 
tissues are mitochondria-rich. Despite expression and regulation of MPCs in 3T3-L1 cells, a white 
adipocyte model, there was minimal expression in either of the WAT depots. During prolonged 
high-fat feeding studies, we confirmed that MPC1 and MPC2 proteins are nutritionally 
downregulated in BAT of male mice during DIO. We suspect that this downregulation is due to 
decreased thermogenic capacity, but further studies are needed to determine this. 
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Additionally, we show that KAT8 is highly expressed in the adipocyte and SVF fractions 
of WAT depots in male and female mice. Our novel data also showed that KAT8 was more highly 
expressed in WAT, more specifically iWAT, than in any other tissue in C57BL/6J mice. Coupled 
with the requirement for adipogenesis, this further suggests that KAT8 plays a prominent role in 
adipocytes. The previously reported male-specific protein (in Drosophila) was not shown to be 
male-specific in C57BL/6J mice, but our data did show enhanced expression in female mice in 
iWAT and rpWAT. Moreover, our data confirm that KAT8 is nutritionally upregulated by DIO 
and refeeding after fasting.    
In order to determine mechanisms by which MPCs and KAT8 are mediating their effects, 
additional studies are required. To further study MPCs, determination of whether substrate bypass 
of the MPC complex or alternative pyruvate transport mechanisms are responsible for 
compensating for the loss of MPC complex functionality in vitro will be important. To assess 
whether the downregulation of MPCs during DIO is due to decreased thermogenic capacity, we 
would need to measure parameters, such as energy expenditure and expression of thermogenic 
genes, in the presence and absence of MPCs in a DIO model. To further study KAT8 interactions 
in adipocytes and determine a mechanism of action, we could perform RNA-Seq experiments in 
the presence and absence of KAT8 expression in adipocytes. Also, the generation of an inducible 
adipose tissue-specific knockout of KAT8 in mice would provide a clear insight into the metabolic 
phenotype of the loss of KAT8 in vitro and further elucidate the role of KAT8 in adipose tissue. 
Although there are currently no mechanistic studies suggesting the role of these proteins in 
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